



The  
Patent  
Office



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ




I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



*P. Mahoney*

Signed

Dated 27 September 1999.


**THIS PAGE BLANK (USPTO)**

# Patents Form 1/77

Patents Act 1977  
(Rule 1)



29DEC98 E414470-31 002246  
\_P01/7700 0.00 - 9828603.2



## Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P005894GB CTH

2. Patent **9828603.2**  
(The Patent Office will fill in this part)

23 DEC 1998

3. Full name, address and postcode of the or of each applicant  
(underline all surnames)

PFIZER LIMITED  
SANDWICH  
KENT  
CT13 9NJ

Patents ADP number (if you know it)

6892473001

If the applicant is a corporate body, give the country/state of its incorporation

UNITED KINGDOM

4. Title of the invention

ENZYME

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)

21 NEW FETTER LANE  
LONDON  
EC4A 1DA

Patents ADP number (if you have one)

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

NO

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form NO

Description 62

Claims(s) 3

Abstract 1

Drawing(s) 9 + 9

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents Form 8A/77  
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date



D YOUNG & CO  
Agents for the Applicants

23 12 98

12. Name and daytime telephone number of the person to contact in the United Kingdom DR C T HARDING

01703 634816

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- Write your answers in capital letters using black ink or you may type them
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

**ENZYME**

The present invention relates to an enzyme. The present invention also relates to a nucleotide sequence encoding same.

5

In particular, the present invention relates to novel nucleic acid sequences encoding novel phosphodiesterase enzymes.

10

The present invention also relates to the use of the novel nucleic acid and amino acid sequences in the diagnosis and treatment of disease.

15

The present invention also relates to the use of the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

20

The present invention further relates to genetically engineered host cells that comprise or express the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

25

Cyclic nucleotide phosphodiesterases (PDEs) are a family of enzymes that catalyse the degradation of cyclic nucleotides. Cyclic nucleotides, particularly cAMP (i.e. cyclic adenosine 3',5'-monophosphate), are important intracellular second messengers. PDEs are one cellular component that regulates the concentration of cyclic nucleotides. In recent years, at least seven PDE enzymes (such as PDEI - PDEVII), as well as many subtypes of these enzymes, have been defined based on substrate affinity and cofactor requirements (Beavo JA and Reifsnyder DH, Trends Pharmacol. Sci. 11:150 [1990]; Beavo J, In: Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action., Beavo J and Housley MD (Eds.). Wiley : Chichester, pp. 3-15 [1990]).

In slightly more detail, examples of PDEs (i.e. cyclic nucleotide phosphodiesterases) include: PDEI which is a  $\text{Ca}^{2+}$ /Calmodulin-dependent PDE; PDEII which is a cGMP stimulated PDE; PDEIII which is a cGMP inhibited PDE; PDEIV which is a high affinity cAMP-specific PDE; and PDEV which is a cGMP specific PDE.

5

Each PDE family may contain two or more isoforms (i.e. there may be two or more PDE isoenzymes). By way of example, mammalian PDE IV, the homologue of the *Drosophila* Dunce gene (Chen CN *et al.*, Proc. Nat. Acad. Sci. (USA) 83:9313 [1986]), is known to have four isoforms in the rat (Swinnen JV *et al.*, Proc. Nat. Acad. Sci. (USA) 86:5325 [1989]). Human PDEs are also known to occur as isoforms and have splice variants. For example, the cloning of one human isoform of PDEIV from monocytes was reported in 1990 (Livi GP *et al.*, Mol. Cell. Bio., 10:2678 [1990]). By way of further example, other workers have independently cloned three splice variants of PDEIV, which are now designated hPDEIV-B1, hPDEIV-B2, and hPDEIV-B3.

15

Teachings on a further cyclic nucleotide phosphodiesterase - namely CN PCDE8 - can be found in WO-A-97/35989. According to WO-A-97/35989, CN PCDE8 has two isozymes - which were designated CN PCDE8A and CN PCDE8B. The term isozyme is sometimes referred to in the art as isoform.

20

According to WO-A-97/35989, many inhibitors of different PDEs have been identified and some have undergone clinical evaluation. For example, PDEIII inhibitors are being developed as antithrombotic agents, as antihypertensive agents and as cardiotonic agents useful in the treatment of congestive heart failure. Rolipram, a PDEIII inhibitor, has been used in the treatment of depression and other inhibitors of PDEIII are undergoing evaluation as anti-inflammatory agents. Rolipram has also been shown to inhibit lipopolysaccharide (LPS) induced TNF-alpha which has been shown to enhance HIV-1 replication *in vitro*. Therefore, rolipram may inhibit HIV-1 replication (Angel *et al* 1995 AIDS 9:1137-44). Additionally, based on its ability to suppress the production of TNF alpha and beta and interferon gamma, rolipram has been shown to be effective in the treatment of encephalomyelitis, the experimental animal model for multiple sclerosis

30

P5894.GB

(Sommer *et al*, 1995 Nat Med 1:244-248) and may be effective in the treatment of tardive dyskinesia (Sasaki *et al*, 1995 Eur J Pharmacol 282:71-76).

According to WO-A-97/35989, there are also non-specific PDE inhibitors such as theophylline, used in the treatment of bronchial asthma and other respiratory diseases, and pentoxifylline, used in the treatment of intermittent claudication and diabetes-induced peripheral vascular disease. Theophylline is thought to act on airway smooth muscle function as well as in an anti-inflammatory or immunomodulatory capacity in the treatment of respiratory diseases (Banner *et al* 1995 Respir J 8:996-1000) where it is thought to act by inhibiting both CN PDE cAMP and cGMP hydrolysis (Banner *et al* 1995 Monaldi Arch Chest Dis 50:286-292). Pentoxifylline, also known to block TNF-alpha production, may inhibit HIV-1 replication (Angel *et al supra*). A list of CN PDE inhibitors is given in Beavo 1995 *supra*.

It has been speculated that selective inhibitors of PDEs, in addition to their isozymes and their subtypes, will lead to more effective therapy with fewer side effects. For example, see the teachings in the reviews of Wieshaar RE *et al*, (J. Med. Chem., 28:537 [1985]), Gienbycz MA (Biochem. Pharm., 43:2041 [1992]) and Lowe JA and Cheng JB (Drugs of the Future, 17:799-807 [1992]).

Thus, for some applications it is desirable to have a selective inhibition of an individual type of PDE. Hence, the cloning and expression of a novel PDE would greatly aid the discovery of selective inhibitors.

According to a first aspect of the present invention there is provided an amino acid sequence comprising the sequence presented as Formula I or a variant, homologue, fragment or derivative thereof.

**Formula I**

An amino acid sequence comprising any one or more of peptide sequences or amino acids Z1 - Z12, any of which peptide sequence or amino acid Z1 - Z12 may be separated from another of said peptide sequence or amino acid Z1 - Z12 by a suitable peptide sequence or amino acid residue;

wherein:

Z1 = MSCLMVERCGE

Z2 = LFE

Z3 = P

Z4 = Q

Z5 = KVCMLGD

Z6 = RLRGQTGV

Z7 = AERRGSPFIDFRLN

Z8 = TT

Z9 = SGEIGTKKKVKRLLSFQRYFHASRLLRGIIPQAPLHLLDEDYLGQARHMLSKVG

Z10 = WDFDIFLFDRLTNGNSLVTLCHLFN

Z11 = HGLIHHFKLDMVTLHRFLVMVQEDYH

Z12 =

NPYHNAVHAADVTOAMHCYLKEPKLASFLTPLDIMLGLLAAAHDVDHPGVNQPFILKTNHHLANLYQNMSVL

and

wherein the amino acid sequence is made up of more than 200 amino acid residues.

The amino acid sequence of the present invention is sometimes referred to as PDE\_XIV.

For convenience, we now present a Table indicating the codes used for the amino acids.



AMINO ACID	THREE LETTER ABBREVIATION	ONE LETTER SYMBOL
Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V
Any residue	Xaa	X

Preferably the amino acid sequence is made up of more than about 230 amino acid residues.

5

Preferably the amino acid sequence is made up of more than about 250 amino acid residues.

Preferably the amino acid sequence is made up of more than about 260 amino acid residues.

10

Preferably the amino acid sequence is made up of at least 268 amino acid residues.

Preferably, the amino acid sequence of Formula I comprises at least one or more of Z7, Z9, Z10, Z11, and Z12, or analogues thereof.

15

P5894.GB

The term "analogue" as used herein means a sequence having a sequence similar to that of Formula I but wherein non-detrimental amino acid substitutions or deletions have been made.

- 5 Preferably, the amino acid sequence of Formula I comprises at least each of Z7, Z9, Z10, Z11, and Z12, or analogues thereof.

Preferably, the amino acid sequence of Formula I comprises at least each of Z1, Z5, Z6, Z7, Z9, Z10, Z11, and Z12, or analogues thereof.

10

Preferably, the amino acid sequence of Formula I comprises at least each of Z1 - Z12, or analogues thereof.

- A preferred example of an amino acid sequence comprising the sequence presented as  
15 Formula I is the amino acid sequence shown as Formula II or a variant, homologue, fragment or derivative thereof.

### Formula II

20 Z1-X1-Z2-X2-Z3-X3-Z4-X4-Z5-X5-Z6-X6-Z7-X7-Z8-X8-Z9-X9-Z10-  
X10-Z11-X11-Z12

wherein

- 25 each of Z1 - Z12 is as defined above; and

each of X1 - X11 is independently selected from a suitable peptide sequence or amino acid.

A more preferred example of an amino acid sequence comprising the sequence presented as Formula I is the amino acid sequence shown as Formula III or a variant, homologue, fragment or derivative thereof.

5

**Formula III**

Z1-X1-Z2-X2-Z3-X3-Z4-X4-Z5-X5-Z6-X6-Z7-X7-Z8-X8-Z9-X9-Z10-  
X10-Z11-X11-Z12

10 wherein

each of Z1 - Z12 is as defined above; and

15 X1 = V or I  
X2 = S or N  
X3 = E or D  
X4 = SV or NA  
X5 = V or I  
X6 = P or R  
20 X7 = N or S  
X8 = H or Y  
X9 = T or M  
X10 = S or T  
X11 = GH or SQ

25

Preferred examples of an amino acid sequence comprising the sequence presented as Formula I include the amino acids shown as: SEQ ID No. 1 or SEQ ID No. 2 or a variant, homologue, fragment or derivative thereof

30 It is to be noted that references to Formula I and/or to any one or more of Formula II - Formula III herein also apply equally to any one or more of: SEQ ID No. 1 or SEQ ID No. 2.

Preferably references to Formula I and/or to any one or more of Formula II - Formula III  
35 herein mean any one or more of: SEQ ID No. 1 or SEQ ID No. 2.

According to a second aspect of the present invention there is provided an amino acid sequence comprising the sequence presented as Formula I.

- 5 According to a third aspect of the present invention there is provided a nucleotide sequence encoding the amino acid sequence of the present invention.

According to a fourth aspect of the present invention there is provided a nucleotide sequence comprising the sequence presented as SEQ ID No. 3 or SEQ ID No. 4 or a  
10 variant, homologue, fragment or derivative thereof.

According to a fifth aspect of the present invention there is provided a nucleotide sequence comprising the sequence presented as SEQ ID No. 1 or SEQ ID No. 4.

- 15 According to a sixth aspect of the present invention there is provided a nucleotide sequence that is capable of hybridising to the nucleotide sequence according to the present invention.

According to a seventh aspect of the present invention there is provided a nucleotide  
20 sequence that is capable of hybridising to the nucleotide sequence according to sixth aspect of the present invention.

According to an eighth aspect of the present invention there is provided a vector comprising the nucleotide sequence according to the present invention.

25

According to a ninth aspect of the present invention there is provided a host cell into which has been incorporated the nucleotide sequence according to the present invention.

According to a tenth aspect of the present invention there is provided an assay method for  
30 identifying an agent that can affect PDE\_XIV activity or expression, the assay method comprising contacting an agent with an amino acid according to the present invention or a nucleotide sequence according to the present invention; and measuring the activity or

P5894.GB

expression of PDE\_XIV; wherein a difference between a) PDE activity or expression in the absence of the agent and b) PDE activity or expression in the presence of the agent is indicative that the agent can affect PDE\_XIV activity or expression.

5 The assay can be used to screen for agents useful in the treatment of CNS disorders. The assay can be used to screen for agents useful in the treatment of cardiovascular disorders. The assay can be used to screen for agents useful in the treatment of gastrointestinal disorders. The assay can be used to screen for agents useful in the treatment of cancer. The assay can be used to screen for agents useful in the treatment of sexual dysfunction -  
10 such as male erectile dysfunction (MED) or female sexual dysfunction.

According to an eleventh aspect of the present invention there is provided a process comprising the steps of: (a) performing the assay according to the present invention; (b) identifying one or more agents that do affect PDE\_XIV activity or expression; and (c)  
15 preparing a quantity of those one or more identified agents.

According to a twelfth aspect of the present invention there is provided a method of affecting *in vivo* PDE\_XIV activity or expression with an agent; wherein the agent is capable of affecting PDE\_XIV activity or expression in an *in vitro* assay method; wherein  
20 the *in vitro* assay method is the assay method of the present invention.

According to a thirteenth aspect of the present invention there is provided the use of an agent in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE\_XIV, the agent is capable of having an effect on the activity  
25 or expression of PDE when assayed *in vitro* by the assay method of the present invention.

According to a fourteenth aspect of the present invention there is provided an enzyme capable of having an immunological reaction with an antibody raised against PDE\_XIV.

30 According to a fifteenth aspect of the present invention there is provided a nucleotide sequence coding for a PDE, wherein the nucleotide sequence is obtainable from NCIMB 40995 or NCIMB 40996.

According to a sixteenth aspect of the present invention there is provided a PDE wherein the PDE is expressable from a nucleotide sequence obtainable from NCIMB 40995 or NCIMB 40996.

5

According to a seventeenth aspect of the present invention there is provided the use of an agent which has an effect on the activity of PDE\_XIV or the expression thereof in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE\_XIV.

10

According to a further aspect of the present invention there is provided

A nucleotide sequence selected from:

- 15 (a) the nucleotide sequence presented as SEQ ID No. 3 or 4, or a variant, homologue, derivative or fragment thereof;
- (b) the nucleotide sequence set out in SEQ ID No. 3 or 4, or the complement thereof;
- (c) a nucleotide sequence capable of hybridising to the nucleotide sequence set out in SEQ ID No. 3 or 4, or a fragment thereof;
- 20 (d) a nucleotide sequence capable of hybridising to the complement of the nucleotide sequence set out in SEQ ID No. 3 or 4, or a fragment thereof; and
- (e) a nucleotide sequence which is degenerate as a result of the genetic code to the nucleotides defined in (a), (b), (c) or (d).

25 Other aspects of the present invention include:

An isolated nucleotide sequence or protein sequence according to the present invention.

30 An assay method for identifying an agent that can affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof,

the assay method comprising

exposing the nucleotide sequence of the present invention or the expression  
5 product ("EP") thereof with an agent;

determining whether the agent modulates (such as affects the expression pattern  
or activity) the nucleotide sequence of the present invention or the expression product  
thereof.

10 An agent identified by the assay method of the present invention.

An agent identified by the assay method of the present invention, which agent has  
hitherto been unknown to have a PDE modulation effect in accordance with the present  
15 invention.

A process comprising the steps of:

(a) performing the assay of the present invention;

20 (b) identifying one or more agents that affect the expression pattern of the nucleotide  
sequence of the present invention or the activity of the expression product thereof;

(c) preparing a quantity of those one or more identified agents.

25 A process comprising the steps of:

(a) performing the assay according to the present invention;

30 (b) identifying one or more agents that affect the expression pattern of the nucleotide  
sequence of the present invention or the activity of the expression product thereof;

(c) preparing a pharmaceutical composition comprising one or more identified agents.

A process comprising the steps of:

(a) performing the assay according to the present invention;

(b) identifying one or more agents that affect the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof;

(c) modifying one or more identified agents to cause a different effect on the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.

Use of an agent identified by an assay according to the present invention in the manufacture of a medicament which affects the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.

A method of treating a target (which target can be a mammal, preferably a human), which method comprises delivering (such as administering or exposing) to the target an effective amount of an agent capable of modulating the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product thereof.

A method of treating a target (which target can be a mammal, preferably a human), which method comprises delivering (such as administering or exposing) to the target an effective amount of an agent identified by an assay according to the present invention.

A method of inducing an immunological response in a subject, the method comprising administering to the subject the nucleotide sequence of the present invention or the expression product thereof.



Broad aspects of the present invention include:

A recombinant PDE\_XIV enzyme.

5 A recombinant nucleotide sequence encoding a PDE\_XIV enzyme.

Preferably the recombinant PDE\_XIV enzyme and/or the recombinant nucleotide sequence of the present invention are a recombinant mammalian PDE\_XIV enzyme and/or a recombinant mammalian nucleotide sequence.

10

In accordance with the present invention, the recombinant PDE\_XIV enzyme has at least the structure presented as Formula I.

Thus the present invention relates to a novel PDE enzyme - which we have called  
15 PDE\_XIV - and to a nucleotide sequence encoding same. The present invention also relates to the use of the novel nucleic acid and amino acid sequences in the diagnosis and treatment of disease. The present invention also relates to the use of the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity. The present invention further relates to genetically  
20 engineered host cells that comprise or express the novel nucleic acid and amino acid sequences to evaluate and/or to screen for agents that can modulate phosphodiesterase activity.

The term "nucleotide sequence" as used herein refers to an oligonucleotide sequence or  
25 polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be DNA or RNA of genomic or synthetic or recombinant origin which may be double-stranded or single-stranded whether representing the sense or antisense strand.

30 Preferably, the term "nucleotide sequence" means DNA.

More preferably, the term "nucleotide sequence" means DNA prepared by use of recombinant DNA techniques (i.e. recombinant DNA).

In a preferred embodiment, the nucleotide sequence *per se* of the present invention does not cover the native nucleotide coding sequence according to the present invention in its natural environment when it is under the control of its native promoter which is also in its natural environment. For ease of reference, we shall call this preferred embodiment the "non-native nucleotide sequence".

As used herein "amino acid sequence" refers to peptide or protein sequences or portions thereof.

In a preferred embodiment, the amino acid sequence *per se* the present invention does not cover the native PDE\_XIV according to the present invention when it is in its natural environment and when it has been expressed by its native nucleotide coding sequence which is also in its natural environment and when that nucleotide sequence is under the control of its native promoter which is also in its natural environment. For ease of reference, we shall call this preferred embodiment the "non-native amino acid sequence".

As used herein, the term "PDE\_XIV" refers to a novel PDE which, up until now, has been uncharacterised. By way of example, we have identified a human PDE\_XIV (sometimes referred to as HSPDE\_XIV). In addition, we have identified a mouse PDE\_XIV (sometimes referred to as MMPDE\_XIV).

For convenience, and unless otherwise stated, reference to PDE\_XIV will include reference to HSPDE\_XIV and/or MMPDE\_XIV.

PDE\_XIV is believed to be present in, and obtainable from, a variety of organs (see the data in Figures 1 - 3; which are discussed in the Experimental Section). We also believe that PDE\_XIV is available from a number of sources in addition to mouse and human - such as any one or more of rat and bovine, ovine, porcine, and equine sources.

P5894.GB

Preferably, the present invention covers mammalian PDE\_XIV which includes but is not limited to any of the above sources.

The PDE\_XIV may be the same as the naturally occurring form - for this aspect, preferably the PDE\_XIV is the non-native amino acid sequence - or is a variant, homologue, fragment or derivative thereof. In addition, or in the alternative, the PDE\_XIV is isolated PDE\_XIV and/or purified PDE\_XIV. The PDE\_XIV can be obtainable from or produced by any suitable source, whether natural or not, or it may be synthetic, semi-synthetic or recombinant.

The PDE\_XIV coding sequence may be the same as the naturally occurring form - for this aspect, preferably the PDE\_XIV coding sequence is the non-native nucleotide sequence - or is a variant, homologue, fragment or derivative thereof. In addition, or in the alternative, the PDE\_XIV coding sequence is an isolated PDE\_XIV coding sequence and/or a purified PDE\_XIV coding sequence. The PDE\_XIV coding sequence can be obtainable from or produced by any suitable source, whether natural or not, or it may be synthetic, semi-synthetic or recombinant.

As used herein "naturally occurring" refers to a PDE\_XIV with an amino acid sequence found in nature.

As used herein "biologically active" refers to a PDE\_XIV having structural, regulatory or biochemical functions (but not necessarily to the same degree) of the naturally occurring PDE\_XIV. Specifically, a PDE\_XIV of the present invention has the ability to hydrolyze a cyclic nucleotide.

As used herein, "immunological activity" is defined as the capability of the natural, recombinant or synthetic PDE\_XIV or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

P5894.GB

The term "derivative" as used herein includes chemical modification of a PDE\_XIV.

Illustrative of such modifications would be replacement of hydrogen by an alkyl, acyl, or amino group.

- 5 As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

The terms "variant", "homologue" or "fragment" in relation to the amino acid sequence for the enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acid from or to the sequence providing the resultant enzyme has PDE\_XIV activity, preferably being at least as biologically active as the enzyme shown as SEQ ID No. 1. or SEQ ID No. 2. In particular, the term "homologue" covers homology with respect to structure and/or function. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as Formula I. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as Formula I. More preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 1. or SEQ ID No. 2. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 1. or SEQ ID No. 2.

With respect to the types of amino acid substitutions that could be made, typically, modifications can be made that maintain the hydrophobicity/hydrophilicity of the amino acid sequence. Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified sequence retains the ability to act as a PDE enzyme in accordance with present invention. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life.

Conservative substitutions may be made, for example according to the Table below.

Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

5

The terms "variant", "homologue" or "fragment" in relation to the nucleotide sequence coding for the preferred enzyme of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having PDE\_XIV activity, preferably being at least as biologically active as the enzyme encoded by the sequences shown as SEQ ID No. 3 or SEQ ID No. 4. In particular, the term "homologue" covers homology with respect to structure and/or function providing the resultant nucleotide sequence codes for or is capable of coding for an enzyme having PDE\_XIV activity. With respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to a nucleotide sequence coding for the amino acid sequence shown as Formula I. More preferably there is at least 95%, more preferably at least 98 homology to a nucleotide sequence coding for the amino acid sequence shown as Formula I. Preferably, with respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequence shown as SEQ ID No. 3 or SEQ ID No. 4. More preferably there is at least 95%, more preferably at least 98%, homology to the sequence shown as SEQ ID No. 3 or SEQ ID No. 4.

P5894.GB

In particular, the term "homology" as used herein may be equated with the term "identity". Here, sequence homology can be determined by a simple "eyeball" comparison (i.e. a strict comparison) of any one or more of the sequences with another sequence to see if that other sequence has at least 75% identity to the sequence(s).

5 Relative sequence homology (i.e. sequence identity) can be determined by commercially available computer programs that can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

Sequence homology (or identity) may even be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html), which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

15 Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

20 BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html)) with a few enhancements. The BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al* (1994) Nature Genetics 6:119-129.

30 The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

P5894.GB

**blastp** - compares an amino acid query sequence against a protein sequence database;

**blastn** - compares a nucleotide query sequence against a nucleotide sequence database;

5 **blastx** - compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

**tblastn** - compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

10

**tblastx** - compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

15

**HISTOGRAM** - Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

20 **DESCRIPTIONS** - Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

25 **ALIGNMENTS** - Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

30 **EXPECT** - The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the

P5894.GB

match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

- 5 **CUTOFF** - Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See  
10 parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

- MATRIX** - Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid  
15 alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

- STRAND** - Restrict a TBLASTN search to just the top or bottom strand of the database  
20 sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

- FILTER** - Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993)  
25 Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g.,  
30 hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.



Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXXX").

5

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

10 It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

15 **NCBI-gi** - Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

20

Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux *et al* 1984 Nucleic Acids Research 12: 387) and FASTA (Atschul *et al* 1990 J Molec Biol 403-410).

25

Should Gap Penalties be used when determining sequence identity, then preferably the following parameters are used:

<b>FOR BLAST</b>	
GAP OPEN	0
GAP EXTENSION	0

<b>FOR CLUSTAL</b>	<b>DNA</b>	<b>PROTEIN</b>	
WORD SIZE	2	1	K triple
GAP PENALTY	10	10	
GAP EXTENSION	0.1	0.1	

As used herein, the terms "variant", "homologue", "fragment" and "derivative" embrace  
 5 allelic variations of the sequences.

The term "variant" also encompasses sequences that are complementary to sequences that  
 are capable of hybridising to the nucleotide sequences presented herein.

10 Preferably, the term "variant" encompasses sequences that are complementary to  
 sequences that are capable of hybridising under stringent conditions (e.g. 65°C and  
 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub> citrate pH 7.0}) to the nucleotide sequences  
 presented herein.

15 The present invention also covers nucleotide sequences that can hybridise to the nucleotide  
 sequences of the present invention (including complementary sequences of those presented  
 herein). In a preferred aspect, the present invention covers nucleotide sequences that can  
 hybridise to the nucleotide sequence of the present invention under stringent conditions  
 (e.g. 65°C and 0.1xSSC).

20

The present invention also relates to nucleotide sequences that are complementary to  
 sequences that can hybridise to the nucleotide sequences of the present invention (including  
 complementary sequences of those presented herein).

25 The term "vector" includes expression vectors and transformation vectors.

The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

5 The term "transformation vector" means a construct capable of being transferred from one species to another.

Thus, the present invention relates to a novel PDE and to a novel nucleic acid sequence encoding same. We have designated this novel PDE as PDE\_XIV.

10 Either or both of the nucleotide sequence coding for PDE\_XIV or the enzyme PDE\_XIV itself may be used to screen for agents that can affect PDE\_XIV activity. In particular, the nucleotide sequence coding for PDE\_XIV or PDE\_XIV itself may be used to screen for agents that can inhibit PDE\_XIV activity. In addition, the nucleotide sequence coding for PDE\_XIV or the enzyme PDE\_XIV itself may be used to screen for agents that selectively  
15 affect PDE\_XIV activity, such as selectively inhibit PDE\_XIV activity.

Furthermore, the nucleotide sequence coding for PDE\_XIV or a sequence that is complementary thereto may also be used in assays to detect the presence of PDE\_XIV coding sequences in human cells. These assays would provide information regarding the  
20 tissue distribution of this enzyme and its biological relevance with respect to particular disease states.

The present invention also covers antibodies to PDE\_XIV (including a derivative, fragment, homologue or variant thereof). The antibodies for PDE\_XIV may be used in  
25 assays to detect the presence of PDE\_XIV in human cells. These assays would provide information regarding the tissue distribution of this enzyme and its biological relevance with respect to particular disease states.

PDE\_XIV is believed to be able to catalyse the conversion of cAMP to AMP. Thus,  
30 PDE\_XIV and/or its coding sequence and/or a sequence capable of hybridising thereto is/are useful for testing the selectivity of drug candidates between different PDEs.

P5894.GB

As indicated, the present invention relates to a DNA sequence (preferably a cDNA sequence) encoding PDE\_XIV. The present invention also relates to DNA segments comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or allelic variations of such sequences.

5

The present invention also relates to polypeptides produced by expression in a host cell into which has been incorporated the foregoing DNA sequences or allelic variations thereof.

10 A highly preferred aspect of the present invention relates to a polypeptide comprising the amino acid sequence of Formula I (such as SEQ ID No. 1 or SEQ ID No. 2). For example, the present invention relates to an isolated polypeptide comprising the amino acid sequence of Formula I (such as SEQ ID No. 1 or SEQ ID No. 2).

15 The present invention also relates to DNA comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof.

The present invention also relates to non-native DNA comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof.

20

A highly preferred aspect of the present invention relates to recombinant DNA comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof.

The present invention also relates to an assay method for detecting the presence of  
25 PDE\_XIV in cells (such as human cells) comprising: (a) performing a reverse transcriptase-polymerase chain reaction on RNA (such as total RNA) from such cells using a pair of polymerase chain reaction primers that are specific for PDE\_XIV, as determined from the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof; and (b) assaying the appearance of an appropriately sized PCR (polymerase chain reaction)  
30 fragment - such as by agarose gel electrophoresis.

P5894.GB

The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that affect (such as inhibit or otherwise modify) the activity of PDE\_XIV and/or the expression thereof, the method comprising contacting PDE\_XIV or the nucleotide sequence coding for same with the agent and then  
5 measuring the activity of PDE\_XIV and/or the expression thereof.

The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit or otherwise modify) the activity of PDE\_XIV and/or the expression thereof, the method  
10 comprising contacting PDE\_XIV or the nucleotide sequence coding for same with the agent and then measuring the activity of PDE\_XIV and/or the expression thereof.

The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that affect (such as inhibit or otherwise  
15 modify) the activity of PDE\_XIV and/or the expression thereof, the method comprising measuring the activity of PDE\_XIV and/or the expression thereof in the presence of the agent or after the addition of the agent in: (a) a cell line into which has been incorporated recombinant DNA comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof, or (b) a cell population or cell line that naturally selectively  
20 expresses PDE\_XIV. Preferably, the activity of PDE\_XIV is determined by the assay method described above.

The present invention also relates to a method of identifying agents (such as compounds, other substances or compositions comprising same) that selectively affect (such as inhibit  
25 or otherwise modify) the activity of PDE\_XIV and/or the expression thereof, the method comprising measuring the activity of PDE\_XIV and/or the expression thereof in the presence of the agent or after the addition of the agent in: (a) a cell line into which has been incorporated recombinant DNA comprising the DNA sequence of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof, or (b) a cell population or cell line that  
30 naturally selectively expresses PDE\_XIV. Preferably, the activity of PDE\_XIV is determined by the assay method described above.

The present invention also relates to nucleotide sequences that are capable of hybridising to all or part of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof. These nucleotide sequences may be used in anti-sense techniques to modify PDE\_XIV expression. Alternatively, these sequences (or portions thereof) can be used as a probe, or  
5 for amplifying all or part of such sequence when used as a polymerase chain reaction primer.

The present invention also provides a diagnostic composition for the detection of PDE\_XIV polynucleotide sequences. The diagnostic composition may comprise the  
10 polynucleotide SEQ ID No. 3 or SEQ ID No. 4 or a variant, homologue, fragment or derivative thereof, or a sequence capable of hybridising to all or part of SEQ ID No. 3 or SEQ ID No. 4 or an allelic variation thereof.

The present invention also provides a method of transforming a host cell with a  
15 nucleotide sequence shown as SEQ ID No. 3 or SEQ ID No. 4 or a derivative, homologue, variant or fragment thereof.

The present invention also provides a method for producing a polypeptide having PDE\_XIV activity, the method comprising the steps of a) transforming a host cell with a  
20 nucleotide sequence shown as SEQ ID No. 3 or SEQ ID No. 4 or a derivative, homologue, variant or fragment thereof; and b) culturing the transformed host cell under conditions suitable for the expression of said polypeptide.

The present invention also provides a method for producing a polypeptide having  
25 PDE\_XIV activity, the method comprising the steps of a) culturing a host cell that has been transformed with a nucleotide sequence shown as SEQ ID No. 3 or SEQ ID No. 4 or a derivative, homologue, variant or fragment thereof under conditions suitable for the expression of said polypeptide; and b) recovering said polypeptide from the host cell culture.

The present invention also provides a method for producing a polypeptide having PDE\_XIV activity, the method comprising the steps of a) transforming a host cell with a nucleotide sequence shown as SEQ ID No. 3 or SEQ ID No. 4 or a derivative, homologue, variant or fragment thereof; b) culturing the transformed host cell under  
5 conditions suitable for the expression of said polypeptide; and c) recovering said polypeptide from the host cell culture.

The present invention also provides a method of screening an agent for modulation (preferably for specific modulation) of PDE\_XIV (or a derivative, homologue, variant or  
10 fragment thereof) activity or the expression of the nucleotide sequence coding for same (including a derivative, homologue, variant or fragment thereof), the method comprising the steps of: a) providing a candidate agent; b) combining PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) with the candidate agent for a  
15 time sufficient to allow modulation under suitable conditions; and c) detecting modulation of the candidate agent to PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) in order to ascertain if the candidate agent modulates PDE\_XIV (or the derivative, homologue, variant or fragment thereof) activity  
20 or the expression of the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof).

The present invention also provides a method of screening an agent for specific binding affinity with PDE\_XIV (or a derivative, homologue, variant or fragment thereof) or the  
25 nucleotide sequence coding for same (including a derivative, homologue, variant or fragment thereof), the method comprising the steps of: a) providing a candidate agent; b) combining PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) with the candidate agent for a time sufficient to allow binding under suitable  
30 conditions; and c) detecting binding of the candidate agent to PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) in order to ascertain

P5894.GB

if the candidate agent binds to PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof).

5 The present invention also provides a method of identifying an agent which is capable of modulating PDE\_XIV, the method comprising the steps of: a) contacting the agent with PDE\_XIV (or a derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof), b) incubating the mixture of step a) with a cyclic nucleotide under conditions suitable for  
10 the hydrolysis of the cyclic nucleotide, c) measuring the amount of cyclic nucleotide hydrolysis, and d) comparing the amount of cyclic nucleotide hydrolysis of step c) with the amount of cyclic nucleotide hydrolysis obtained with PDE\_XIV (or the derivative, homologue, variant or fragment thereof) or the nucleotide sequence coding for same (or the derivative, homologue, variant or fragment thereof) incubated without the compound,  
15 thereby determining whether the agent affects (such as stimulates or inhibits) cyclic nucleotide hydrolysis.

The agent of the present invention can be, for example, an organic compound or an inorganic compound. The agent can be, for example, a nucleotide sequence that is anti-  
20 sense to all or part of the sequence shown as SEQ ID No. 3 or SEQ ID No. 4.

The present invention also provides a pharmaceutical composition for treating an individual in need of same due to PDE\_XIV activity, the composition comprising a therapeutically effective amount of an agent that affects (such as inhibits) said activity  
25 and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

Thus, the present invention also covers pharmaceutical compositions comprising the agents of the present invention (an agent capable of modulating the expression pattern of the nucleotide sequence of the present invention or the activity of the expression product  
30 thereof and/or an agent identified by an assay according to the present invention). In this regard, and in particular for human therapy, even though the agents of the present invention can be administered alone, they will generally be administered in admixture



P5894.GB

with a pharmaceutical carrier, excipient or diluent selected with regard to the intended route of administration and standard pharmaceutical practice.

By way of example, in the pharmaceutical compositions of the present invention, the agents of the present invention may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), or solubilising agent(s).

In general, a therapeutically effective daily oral or intravenous dose of the agents of the present invention is likely to range from 0.01 to 50 mg/kg body weight of the subject to be treated, preferably 0.1 to 20 mg/kg. The agents of the present invention may also be administered by intravenous infusion, at a dose which is likely to range from 0.001-10 mg/kg/hr.

Tablets or capsules of the agents may be administered singly or two or more at a time, as appropriate. It is also possible to administer the agents of the present invention in sustained release formulations.

Typically, the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intracavernosally, intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or

monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

- 5 For some applications, preferably the compositions are administered orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents.
- 10 For parenteral administration, the compositions are best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood.

For buccal or sublingual administration the compositions may be administered in the  
15 form of tablets or lozenges which can be formulated in a conventional manner.

For oral, parenteral, buccal and sublingual administration to subjects (such as patients), the daily dosage level of the agents of the present invention may typically be from 10 to 500 mg (in single or divided doses). Thus, and by way of example, tablets or capsules  
20 may contain from 5 to 100 mg of active agent for administration singly, or two or more at a time, as appropriate. As indicated above, the physician will determine the actual dosage which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. It is to be noted that whilst the above-mentioned dosages are exemplary of the average case there can, of course, be individual  
25 instances where higher or lower dosage ranges are merited and such dose ranges are within the scope of this invention.

Generally, in humans, oral administration of the agents of the present invention is the preferred route, being the most convenient and, for example in MED, avoiding the well-  
30 known disadvantages associated with intracavernosal (i.c.) administration. A preferred oral dosing regimen for a typical patient could be from 25 to 100 mg of agent when required. In circumstances where the recipient suffers from a swallowing disorder or

from impairment of drug absorption after oral administration, the drug may be administered parenterally, e.g. sublingually or buccally.

For veterinary use, the agent of the present invention is typically administered as a suitably acceptable formulation in accordance with normal veterinary practice and the veterinary surgeon will determine the dosing regimen and route of administration which will be most appropriate for a particular animal. However, as with human treatment, it may be possible to administer the agent alone for veterinary treatments.

Typically, the pharmaceutical compositions - which may be for human or animal usage - will comprise any one or more of a pharmaceutically acceptable diluent, carrier, excipient or adjuvant. The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. As indicated above, the pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

In some embodiments of the present invention, the pharmaceutical compositions will comprise one or more of: an agent that has been screened by an assay of the present invention; an agent that is capable of interacting with any one or more of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4 including derivatives, fragments, homologues or variants thereof or sequences capable of hybridising to SEQ ID No. 3 or SEQ ID No. 4.

Thus the invention provides a pharmaceutical composition comprising an agent of the present invention (or even a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof) together with a pharmaceutically acceptable diluent, excipient or carrier.

The pharmaceutical composition could be for veterinary (i.e. animal) usage or for human usage.

The invention further provides an agent of the present invention (or even a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof) or a pharmaceutical composition containing any of the foregoing, for use as a medicament.

5

The present invention also provides the use of an agent to affect PDE\_XIV activity (such as to inhibit, modulate or agonise) in the stratum of the brain.

10 The present invention also provides a method of treating an individual in need of same due to PDE\_XIV activity comprising administering to said individual an effective amount of the pharmaceutical composition of the present invention.

15 Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

20 Despite the fact that WO-A-97/35989 does not teach or suggest the presence of PDE\_XIV, let alone the sequence for same or the nucleotide sequence coding for same, this document provides some useful background teachings on cyclic nucleotide phosphodiesterases and nucleotide sequences coding for same, as well as on their uses. Some of those teachings have been presented in some of the following description - but with reference to the cyclic nucleotide phosphodiesterase and nucleotide sequence coding for same of the present invention.

25

In accordance with the present invention, PDE\_XIV polynucleotide sequences which encode PDE\_XIV, fragments of the polypeptide, fusion proteins or functional equivalents thereof, may be used to generate recombinant DNA molecules that direct the expression of PDE\_XIV in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used to clone and express PDE\_XIV. As will be understood by those of skill in the art, it may be advantageous to

30

P5894.GB

produce PDE-encoding nucleotide sequences possessing non-naturally occurring codons. Codons preferred by a particular prokaryotic or eukaryotic host (Murray E *et al* (1989) Nuc. Acids Res. 17:477-508) can be selected, for example, to increase the rate of PDE\_XIV expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally occurring sequence.

Also included within the scope of the present invention are polynucleotide sequences that are capable of hybridizing to the nucleotide sequence of SEQ ID No.3 or SEQ ID No. 4 under conditions of intermediate to maximal stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

Maximum stringency typically occurs at about  $T_m - 5^\circ\text{C}$  ( $5^\circ\text{C}$  below the  $T_m$  of the probe); high stringency at about  $5^\circ\text{C}$  to  $10^\circ\text{C}$  below  $T_m$ ; intermediate stringency at about  $10^\circ\text{C}$  to  $20^\circ\text{C}$  below  $T_m$ ; and low stringency at about  $20^\circ\text{C}$  to  $25^\circ\text{C}$  below  $T_m$ . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a PDE\_XIV protein and hybridise to the DNA sequences set forth as SEQ ID No. 3 or SEQ ID No. 4, or a selected fragment of said DNA sequence. Preferred are such sequences encoding PDE\_XIV which hybridise under high-stringency conditions to the sequence of SEQ ID No. 3 or SEQ ID No. 4.

Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature

(T<sub>m</sub>) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

5

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na<sup>+</sup> at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na<sup>+</sup> pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

15 Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

20 Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, 25 e.g. Sambrook, et al., eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, et al., eds. (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the 30 probe also play a role.

P5894.GB

Advantageously, the invention moreover provides nucleic acid sequence which are capable of hybridising, under stringent conditions, to a fragment of SEQ. ID. No. 3 or SEQ ID No. 4. Preferably, the fragment is between 15 and 50 bases in length. Advantageously, it is about 25 bases in length.

5

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY) as well as the process of amplification as carried out in polymerase chain reaction technologies as described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

10

15

As used herein a "deletion" is defined as a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

20

As used herein an "insertion" or "addition" is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring PDE.

25

30

Altered PDE\_XIV polynucleotide sequences which may be used in accordance with the invention include deletions, insertions or substitutions of different nucleotide residues resulting in a polynucleotide that encodes the same or a functionally equivalent PDE. The protein may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PDE. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of PDE is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids

P5894.GB

include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

5 Included within the scope of the present invention are alleles of PDE. As used herein, an "allele" or "allelic sequence" is an alternative form of PDE. Alleles result from a mutation, i.e., a change in the nucleic acid sequence, and generally produce altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes  
10 which give rise to alleles are generally ascribed to deletions, additions or substitutions of amino acids. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

The nucleotide sequences of the present invention may be engineered in order to alter a  
15 PDE coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis to insert new restriction sites, to alter glycosylation patterns or to change codon preference.

20

In another embodiment of the invention, a PDE natural, modified or recombinant sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for inhibitors of PDE activity, it may be useful to encode a chimeric PDE protein expressing a heterologous epitope that is  
25 recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between a PDE sequence and the heterologous protein sequence, so that the PDE may be cleaved and purified away from the heterologous moiety.

30 In an alternative embodiment of the invention, the coding sequence of PDE could be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers MH *et al* (1980) Nuc Acids Res Symp Ser 215-23, Horn T *et al* (1980) Nuc



P5894.GB

Acids Res Symp Ser 225-232). Alternatively, the protein itself could be produced using chemical methods to synthesize a PDE amino acid sequence, in whole or in part. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., Creighton  
5 (1983) *Proteins Structures And Molecular Principles*, WH Freeman and Co, New York NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, *supra*).

Direct peptide synthesis can be performed using various solid-phase techniques (Roberge  
10 JY *et al* (1995) *Science* 269: 202-204) and automated synthesis may be achieved, for example, using the ABI 431 A Peptide Synthesizer (Perkin Elmer) in accordance with the instructions provided by the manufacturer. Additionally, the amino acid sequence of PDE, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with a sequence from other subunits, or any part thereof, to produce a  
15 variant polypeptide.

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression should be confirmed. For example, if the PDE coding sequence is inserted within a marker gene sequence, recombinant cells  
20 containing PDE coding regions can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a PDE coding sequence under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of PDE as well.

25 Alternatively, host cells which contain the coding sequence for PDE and express PDE coding regions may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridization and protein bioassay or immunoassay techniques which include membrane-based, solution-based, or chip-based technologies for the detection and/or quantification  
30 of the nucleic acid or protein.

P5894.GB

The presence of the PDE polynucleotide coding sequence can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes, portions or fragments of the sequence presented as SEQ ID No. 3 or SEQ ID No. 4. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the PDE coding sequence to detect transformants containing PDE DNA or RNA. As used herein "oligonucleotides" or "oligomers" may refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides which can be used as a probe or amplifier. Preferably, oligonucleotides are derived from the 3' region of the nucleotide sequence shown as SEQ ID No: 3 or SEQ ID No. 4.

A variety of protocols for detecting and measuring the expression of PDE polypeptide, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on PDE polypeptides is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton R *et al* (1990, Serological Methods, A Laboratory Manual, APS Press, St Paul MN) and Maddox DE *et al* (1983, J Exp Med 15 8:121 1).

A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic and amino acid assays. Means for producing labelled hybridization or PCR probes for detecting PDE polynucleotide sequences include oligolabelling, nick translation, end-labelling or PCR amplification using a labelled nucleotide. Alternatively, the PDE coding sequence, or any portion of it, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3 or SP6 and labeled nucleotides.

P5894.GB

A number of companies such as Pharmacia Biotech (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for these procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241. Also, recombinant immunoglobulins may be produced as shown in US Patent No. 4,816,567.

Host cells transformed with a PDE nucleotide coding sequence may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The protein produced by a recombinant cell may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing PDE coding sequences can be designed with signal sequences which direct secretion of PDE coding sequences through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join PDE coding sequence to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll *DJ et al* (1993) *DNA Cell Biol* 12:441-53, see also above discussion of vectors containing fusion proteins).

The PDE may also be expressed as a recombinant protein with one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals (Porath J (1992) *Protein Expr Purif* 3 -.26328 1), protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle, WA). The inclusion of a cleavable linker sequence such as Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and PDE is useful to facilitate purification.

P5894.GB

Specific amino acid sequences of PDE\_XIV are shown as SEQ ID No. 1 and SEQ ID No. 2. However, the present invention encompasses amino acid sequences encoding other members from the PDE\_XIV family which would include amino acid sequences having at least 60% identity (more preferably at least 75% identity) to the amino acid sequence of SEQ ID Nos. 1 or 2. As indicated, suitable generic formulae for the PDE\_XIV family in accordance with the present invention are presented as Formula I or any one of Formula II-Formula III.

In an embodiment of the present invention, PDE\_XIV or a variant, homologue, fragment or derivative thereof and/or a cell line that expresses the PDE\_XIV or variant, homologue, fragment or derivative thereof may be used to screen for antibodies, peptides, or other agent, such as organic or inorganic molecules, that act as modulators of phosphodiesterase activity or for the expression thereof, thereby identifying a therapeutic agent capable of modulating cyclic nucleotide levels. For example, anti-PDE\_XIV antibodies capable of neutralizing the activity of PDE\_XIV may be used to inhibit PDE\_XIV hydrolysis of cyclic nucleotides, thereby increasing their levels. Alternatively, screening of peptide libraries or organic libraries made by combinatorial chemistry with recombinantly expressed PDE\_XIV or a variant, homologue, fragment or derivative thereof or cell lines expressing PDE\_XIV or a variant, homologue, fragment or derivative thereof may be useful for identification of therapeutic agents that function by modulating PDE\_XIV hydrolysis of cyclic nucleotides. Synthetic compounds, natural products, and other sources of potentially biologically active materials can be screened in a number of ways deemed to be routine to those of skill in the art. For example, nucleotide sequences encoding the N-terminal region of PDE\_XIV may be expressed in a cell line which can be used for screening of allosteric modulators, either agonists or antagonists, of PDE\_XIV activity. Alternatively, nucleotide sequences encoding the conserved catalytic domain of PDE\_XIV can be expressed in cell lines and used to screen for inhibitors of cyclic nucleotide hydrolysis.

The ability of a test agent to interfere with PDE\_XIV activity or cyclic nucleotide hydrolysis may be determined by measuring PDE\_XIV levels or cyclic nucleotide levels (as disclosed in Smith *et al* 1993 Appl. Biochem. Biotechnol. 41:189-218). There are

also commercially available immunoassay kits for the measurement of cAMP and cGMP (eg Amersham International, Arlington Heights, IL and DuPont, Boston, MA). The activity of PDE\_XIV may also be monitored by measuring other responses such as phosphorylation or dephosphorylation of other proteins using conventional techniques developed for these purpose.

Accordingly, the present invention provides a method of identifying a compound which is capable of modulating the cyclic nucleotide phosphodiesterase activity of a PDE\_XIV, or a variant, homologue, fragment or derivative thereof, comprising the steps of a) contacting the compound with a PDE\_XIV, or a variant, homologue, fragment or derivative thereof; b) incubating the mixture of step a) with a cyclic nucleotide under conditions suitable for the hydrolysis of the cyclic nucleotide; c) measuring the amount of cyclic nucleotide hydrolysis; and d) comparing the amount of cyclic nucleotide hydrolysis of step c) with the amount of cyclic nucleotide hydrolysis obtained with the PDE\_XIV, or a variant, homologue, fragment or derivative thereof, incubated without the compound, thereby determining whether the compound stimulates or inhibits cyclic nucleotide hydrolysis. In one embodiment of the method, the fragment may be from the N-terminal region of the PDE\_XIV and provides a method to identify allosteric modulators of the PDE\_XIV. In another embodiment of the present invention, the fragment may be from the carboxy terminal region of the PDE\_XIV and provides a method to identify inhibitors of cyclic nucleotide hydrolysis.

Procedures well known in the art may be used for the production of antibodies to PDE\_XIV polypeptides. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments and fragments produced by a Fab expression library. Neutralizing antibodies, i.e., those which inhibit biological activity of PDE polypeptides, are especially preferred for diagnostics and therapeutics.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc. may be immunized by injection with PDE\_XIV polypeptide or any portion, variant, homologue, fragment or derivative thereof or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase

immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminium hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. BCG (*Bacilli Calmette-Guerin*) and *Corynebacterium parvum* are potentially useful human adjuvants which may be employed if purified PDE polypeptide is administered to immunologically compromised individuals for the purpose of stimulating systemic defence.

Monoclonal antibodies to PDE\_XIV polypeptide may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique originally described by Koehler and Milstein (1975 *Nature* 256:495-497), the human B-cell hybridoma technique (Kosbor *et al* (1983) *Immunol Today* 4:72; Cote *et al* (1983) *Proc Natl Acad Sci* 80:2026-2030) and the EBV-hybridoma technique (Cole *et al* (1985) *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss Inc, pp 77-96). In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison *et al* (1984) *Proc Natl Acad Sci* 81:6851-6855; Neuberger *et al* (1984) *Nature* 312:604-608; Takeda *et al* (1985) *Nature* 314:452-454). Alternatively, techniques described for the production of single chain antibodies (US Patent No. 4,946,779) can be adapted to produce PDE\_XIV specific single chain antibodies.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in Orlandi *et al* (1989, *Proc Natl Acad Sci* 86: 3833-3837), and Winter G and Milstein C (1991; *Nature* 349:293-299).

Antibody fragments which contain specific binding sites for PDE\_XIV may also be generated. For example, such fragments include, but are not limited to, the  $F(ab')_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$

fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse WD *et al* (1989) Science 256:1275-128 1).

5 PDE\_XIV-specific antibodies are useful for the diagnosis of conditions and diseases associated with expression of PDE\_XIV polypeptide. A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the formation of complexes between PDE\_XIV polypeptides and its  
10 specific antibody (or similar PDE\_XIV-binding molecule) and the measurement of complex formation. A two-site, monoclonal based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific PDE\_XIV protein is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox DE *et al* (1983, J Exp Med 158:121 1).

15 Anti-PDE\_XIV antibodies are useful for the diagnosis of inflammation, conditions associated with proliferation of hematopoietic cells and HIV infection or other disorders or diseases characterized by abnormal expression of a PDE\_XIV. Diagnostic assays for a PDE\_XIV include methods utilizing the antibody and a label to detect a PDE\_XIV  
20 polypeptide in human body fluids, cells, tissues or sections or extracts of such tissues. The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, the polypeptides and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known to those of skill in the art.

25 A variety of protocols for measuring a PDE\_XIV polypeptide, using either polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay  
30 utilizing monoclonal antibodies reactive to two non-interfering epitopes on a PDE\_XIV polypeptide is preferred, but a competitive binding assay may be employed. These

P5894.GB

assays are described, among other places, in Maddox, DE *et al* (1983, J Exp Med 158:121 1).

In order to provide a basis for the diagnosis of disease, normal or standard values from a PDE\_XIV polypeptide expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with antibody to a PDE\_XIV polypeptide under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by comparing it to a dilution series of positive controls where a known amount of antibody is combined with known concentrations of a purified PDE\_XIV polypeptide. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by a disorder or disease related to a PDE\_XIV polypeptide expression. Deviation between standard and subject values establishes the presence of the disease state.

A PDE\_XIV polypeptide, its immunogenic fragments or oligopeptides thereof can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The polypeptide employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The abolition of activity or the formation of binding complexes between a PDE\_XIV polypeptide and the agent being tested may be measured.

Accordingly, the present invention provides a method for screening one or a plurality of compounds for modulation (preferably specific modulation, such as specific binding affinity) of PDE\_XIV or the expression thereof, or a portion thereof or variant, homologue, fragment or derivative thereof, comprising providing one or a plurality of compounds; combining a PDE\_XIV or a nucleotide sequence coding for same or a portion thereof or variant, homologue, fragment or derivative thereof with the or each of a plurality of compounds for a time sufficient to allow modulation under suitable conditions; and detecting binding of a PDE\_XIV, or portion thereof or variant, homologue, fragment or derivative thereof, to each of the plurality of compounds, thereby identifying the compound or compounds which modulate a PDE\_XIV or a



nucleotide sequence coding for same. In such an assay, the plurality of compounds may be produced by combinatorial chemistry techniques known to those of skill in the art.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the PDE\_XIV polypeptides and is based upon the method described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with PDE\_XIV fragments and washed. A bound PDE\_XIV is then detected - such as by appropriately adapting methods well known in the art. A purified PDE\_XIV can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding a PDE\_XIV specifically compete with a test compound for binding a PDE\_XIV. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with a PDE\_XIV.

A PDE\_XIV polynucleotide, or any part thereof, may provide the basis for a diagnostic and/or a therapeutic compound. For diagnostic purposes, PDE\_XIV polynucleotide sequences may be used to detect and quantitate gene expression in conditions, disorders or diseases in which PDE\_XIV activity may be implicated, for example, in CNS disorder, cardiovascular disorder, GI disorders, cancer, male erectile dysfunction.

Included in the scope of the invention are oligonucleotide sequences, antisense RNA and DNA molecules and ribozymes, which function to destabilize PDE\_XIV mRNA or inhibit translation of a PDE\_XIV. Such nucleotide sequences may be used in conditions where it would be preferable to increase cyclic nucleotide levels, such as in inflammation.

Another aspect of the subject invention is to provide for nucleic acid hybridization or PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PDE coding region or closely related molecules, such as alleles.

The specificity of the probe, i.e., whether it is derived from a highly conserved, conserved or non-conserved region or domain, and the stringency of the hybridization or amplification (high, intermediate or low) will determine whether the probe identifies only naturally occurring PDE coding sequence, or related sequences. Probes for the detection of related nucleic acid sequences are selected from conserved or highly conserved nucleotide regions of cyclic nucleotide PDE family members, such as the 3' region, and such probes may be used in a pool of degenerate probes. For the detection of identical nucleic acid sequences, or where maximum specificity is desired, nucleic acid probes are selected from the non-conserved nucleotide regions or unique regions of PDE polynucleotides. As used herein, the term "non-conserved nucleotide region" refers to a nucleotide region that is unique to the PDE coding sequence disclosed herein and does not occur in related family members, such as known cyclic nucleotide PDEs.

A PDE\_XIV encoding polynucleotide sequence may be used for the diagnosis of diseases resulting from expression of PDE\_XIV. For example, polynucleotide sequences encoding PDE\_XIV may be used in hybridization or PCR assays of tissues from biopsies or autopsies or biological fluids, such as serum, synovial fluid or tumor biopsy, to detect abnormalities in PDE\_XIV expression. The form of such qualitative or quantitative methods may include Southern or northern analysis, dot blot or other membrane-based technologies; PCR technologies; dip stick, pin or chip technologies; and ELISA or other multiple sample formal technologies. All of these techniques are well known in the art and are in fact the basis of many commercially available diagnostic kits.

Such assays may be tailored to evaluate the efficacy of a particular therapeutic treatment regime and may be used in animal studies, in clinical trials, or in monitoring the treatment of an individual patient. In order to provide a basis for the diagnosis of disease, a normal or standard profile for PDE expression must be established. This is accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with PDE\_XIV or a portion thereof, under conditions suitable

P5894.GB

for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained for normal subjects with a dilution series of positive controls run in the same experiment where a known amount of purified PDE\_XIV is used. Standard values obtained from normal samples may be compared with values  
5 obtained from samples from subjects potentially affected by a disorder or disease related to expression of the PDE coding sequence. Deviation between standard and subject values establishes the presence of the disease state. If disease is established, an existing therapeutic agent is administered, and treatment profile or values may be generated. Finally, the assay may be repeated on a regular basis to evaluate whether the values  
10 progress toward or return to the normal or standard pattern. Successive treatment profiles may be used to show the efficacy of treatment over a period of several days or several months.

PCR as described in US Patent Nos. 4,683,195; 4,800,195; and 4,965,188 provides  
15 additional uses for oligonucleotides based upon the PDE\_XIV sequence. Such oligomers are generally chemically synthesized, but they may be generated enzymatically or produced from a recombinant source. Oligomers generally comprise two nucleotide sequences, one with sense orientation (5'→3') and one with antisense (3'←5') employed under optimized conditions for identification of a specific gene or condition.  
20 The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Additional methods to quantitate the expression of a particular molecule include  
25 radiolabeling (Melby PC *et al* 1993 J Immunol Methods 159:235-44) or biotinylating (Duplaa C *et al* 1993 Anal Biochem 229-36) nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated. Quantitation of multiple samples may be speeded up by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a  
30 spectrophotometric or calorimetric response gives rapid quantitation.

A PDE\_XIV antisense molecule may provide the basis for treatment of various abnormal conditions related to, for example, increased PDE\_XIV activity - such as CNS disorder, cardiovascular disorder, GI disorders, cancer, male erectile dysfunction.

- 5 Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of recombinant PDE\_XIV sense or antisense molecules to the targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant vectors containing PDE\_XIV. Alternatively, recombinant PDE\_XIV can be delivered to target cells in  
10 liposomes.

The full length cDNA sequence and/or its regulatory elements enable researchers to use PDE\_XIV as a tool in sense (Youssofian H and HF Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi *et al* (1991) Annu Rev Biochem 60:631-652) investigations of  
15 gene function. Oligonucleotides, designed from the cDNA or control sequences obtained from the genomic DNA can be used *in vitro* or *in vivo* to inhibit expression. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions. Appropriate oligonucleotides, which can be 20 nucleotides in length, may be  
20 used to isolate PDE\_XIV sequences or closely related molecules from human libraries.

Additionally, PDE\_XIV expression can be modulated by transfecting a cell or tissue with expression vectors which express high levels of a PDE\_XIV fragment in conditions where it would be preferable to block phosphodiesterase activity thereby increasing  
25 cyclic nucleotide levels. Such constructs can flood cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies of the vector are disabled by endogenous nucleases. Such transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the  
30 vector system.

P5894.GB

Modifications of gene expression can be obtained by designing antisense sequences to the control regions of the PDE gene, such as the promoters, enhancers, and introns.

Oligonucleotides derived from the transcription initiation site, e.g., between -10 and +10 regions of the leader sequence, are preferred. Antisense RNA and DNA molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes. Similarly, inhibition can be achieved using Hogeboom base-pairing methodology, also known as "triple helix" base pairing. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by a endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of PDE RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide sequence inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Both antisense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* or *in vivo* transcription of DNA sequences encoding the antisense RNA

P5894.GB

molecule. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues.

5

DNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule.

10

Methods for introducing vectors into cells or tissue include those methods discussed herein. In addition, several of these transformation or transfection methods are equally suitable for *ex vivo* therapy,

15 The nucleic acid sequence for PDE\_XIV can also be used to generate hybridization probes as previously described, for mapping the endogenous genomic sequence. The sequence may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. These include *in situ* hybridization to chromosomal spreads (Verma *et al* (1988) Human Chromosomes: A Manual of Basic  
20 Techniques, Pergamon Press, New York City), flow-sorted chromosomal preparations, or artificial chromosome constructions such as YACs, bacterial artificial chromosomes (BACs), bacterial PI constructions or single chromosome cDNA libraries.

*In situ* hybridization of chromosomal preparations and physical mapping techniques such  
25 as linkage analysis using established chromosomal markers are invaluable in extending genetic maps. Examples of genetic maps can be found in Science (1995; 270:410f and 1994; 265:1981f). Often the placement of a gene on the chromosome of another mammalian species may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to  
30 chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once a disease or syndrome, such as ataxia telangiectasia

P5894.GB

(AT), has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti *et al* (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to  
5 detect differences in the chromosomal location due to translocation, inversion, etc between normal, carrier or affected individuals.

Genomic sequences are also of utility in the context of drug discovery. It may be valuable to inhibit the mRNA transcription of a particular isoform rather than to inhibit its translated  
10 protein. This is particularly true with PDE\_XIV, since the different splice variants may be transcribed from different promoters. There is precedent for multiple promoters directing the transcription of a mouse brain 2',3'-cyclic-nucleotide 3' phosphodiesterase (Kurihara T *et al.*, Biochem. Biophys. Res. Comm. 170:1074 [1990]).

15 Another utility of the invention is that the DNA sequences, once known, give the information that may be needed to design assays to specifically detect isoenzymes or splice variants. Isozyme-specific PCR primer pairs are but one example of an assay that depends completely on the knowledge of the specific DNA sequence of the isozyme or splice variant. Such an assay allows detection of mRNA for the isozyme to access the tissue  
20 distribution and biological relevance of each isozyme to a particular disease state. It also allows identification of cell lines that may naturally express only one isozyme - a discovery that might obviate the need to express recombinant genes. If specific PDE\_XIV isozymes are shown to associated with a particular disease state, the invention would be valuable in the design of diagnostic assays to detect the presence of isozyme mRNA.

25 An abnormal level of nucleotide sequences encoding a PDE\_XIV in a biological sample may reflect a chromosomal aberration, such as a nucleic acid deletion or mutation. Accordingly, nucleotide sequences encoding a PDE\_XIV provide the basis for probes which can be used diagnostically to detect chromosomal aberrations such as deletions,  
30 mutations or chromosomal translocations in the gene encoding PDE. PDE\_XIV gene expression may be altered in such disease states or there may be a chromosomal aberration present in the region of the gene encoding a PDE\_XIV.

A PDE\_XIV nucleic acid antisense molecule may be used to block the activity of the PDE\_XIV in conditions where it would be preferable to elevate cyclic nucleotide levels.

5 The present invention also relates to the use of genetically engineered host cells expressing a PDE\_XIV or variant, homologue, fragment or derivative thereof in screening methods for the identification of inhibitors and antagonists of the PDE\_XIV that would modulate phosphodiesterase activity thereby modulating cyclic nucleotide levels. Such genetically engineered host cells could be used to screen peptide libraries  
10 or organic molecules capable of modulating PDE\_XIV activity. Antagonists and inhibitors of PDE\_XIV, such as antibodies, peptides or small organic molecules will provide the basis for pharmaceutical compositions for the treatment of diseases associated with, for example, CNS disorder, cardiovascular disorder, GI disorders, cancer, male erectile dysfunction. Such inhibitors or antagonists can be administered  
15 alone or in combination with other therapeutics for the treatment of such diseases.

The present invention also relates to expression vectors and host cells comprising polynucleotide sequences encoding PDE\_XIV or variant, homologue, fragment or derivative thereof for the *in vivo* or *in vitro* production of PDE\_XIV protein or to screen  
20 for agents that can affect PDE\_XIV expression or activity.

Additionally, the present invention relates to the use of a PDE\_XIV polypeptide, or variant, homologue, fragment or derivative thereof, to produce anti-PDE\_XIV antibodies which can, for example, be used diagnostically to detect and quantitate PDE\_XIV levels  
25 in disease states.

The present invention also relates to pharmaceutical compositions comprising effective amounts of inhibitors or antagonists of PDE\_XIV protein (including anti-sense nucleic acid sequences) in admixture with a pharmaceutically acceptable diluent, carrier,  
30 excipient or adjuvant (including combinations thereof).



P5894.GB

The present invention relates to pharmaceutical compositions which may comprise all or portions of PDE\_XIV polynucleotide sequences, PDE\_XIV antisense molecules, PDE\_XIV polypeptides, protein, peptide or organic modulators of PDE\_XIV bioactivity, such as inhibitors, antagonists (including antibodies) or agonists, alone or in combination with at least one other agent, such as stabilizing compound, and may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.

The present invention further provides diagnostic assays and kits for the detection of PDE\_XIV in cells and tissues comprising a purified PDE\_XIV which may be used as a positive control, and anti-PDE\_XIV antibodies. Such antibodies may be used in solution-based, membrane-based, or tissue-based technologies to detect any disease state or condition related to the expression of PDE\_XIV protein or expression of deletions or a variant, homologue, fragment or derivative thereof.

The following samples were deposited in accordance with the Budapest Treaty at the recognised depositary The National Collections of Industrial and Marine Bacteria Limited (NCIMB) at 23 St. Machar Drive, Aberdeen, Scotland, United Kingdom, AB2 1RY on 18 December 1998:

<i>E. coli</i> pHS-PDE_XIV	NCIMB number NCIMB 40995
<i>E. coli</i> pMM-PDE_XIV	NCIMB number NCIMB 40996

The present invention also encompasses sequences derivable and/or expressable from those deposits and embodiments comprising the same.

The present invention will now be described by way of example, in which reference is made to the following Figures:

Figure 1 which presents a photographic image

Figure 2 which presents a photographic image;

Figure 3 which presents a Table and a photographic image;

Figure 4 which presents an alignment of nucleotide sequences;

5

Figure 5 which presents an alignment of protein sequences; and

Figure 6 which presents a graph.

## 10 Northern Hybridisation and Probe preparation

Northern blots, obtained from Clontech, were prehybridised for 1 hour in ExpressHyb hybridisation solution (Clontech) at 55°C before a radiolabelled new PDE fragment (DNA was labelled using the Megaprime random labelling system (Amersham) strictly following the manufacturers instructions with 50uCi of <sup>32</sup>P-dATP) was added to fresh Expresshyb and hybridised to the blot overnight at 55°C, with gentle shaking. Blots were then washed 3X at room temperature for 10 minutes each in 2XSSC (150 mM NaCl, 30 mM Na.citrate) followed by 2 washes in 0.2XSSC (15 mM NaCl, 3 mM Na.citrate) at 55°C for 20 minutes each. Blots were then exposed to autoradiographic film.

20

## Polymerase Chain Reactions (PCR)

PCRs were performed using standard reagents and conditions. Briefly, all reaction buffers and enzymes were obtained in kit format from either Clontech (for rapid amplification of cDNA ends (RACE) reactions) or from Life technologies for standard PCR. Oligonucleotides were obtained from a commercial supplier (OSWEL DNA services) and used at a concentration of 400nM. Reactions were performed on a MJ Research PTC-200 thermal cycler, using cycling parameters as recommended by the manufacturer of the kit being used.

30

### **The identification of new PDE.**

The clone (IMAGE clone id 1364394) was obtained from Research Genetics (2130, Memorial Pkwy, SW Huntsville, AL 358801, USA) as a stab culture in L-agar. Bacteria from the stab culture were streaked onto a 37 mm L-agar plate in the presence of ampicillin at a concentration of 100mg/ml. After overnight growth at 37°C a single clone was picked, using sterile technique, into 5ml of LB-broth containing ampicillin at a concentration of 100 mg/ml and grown at 37°C overnight with shaking (220 rpm). Plasmid DNA was isolated from the bacteria using a standard commercially available miniprep kit (Qiagen<sup>TM</sup>) and strictly following the manufacturers instructions. The isolated DNA was then subjected to full length sequencing, using standard proprietary kits and reagents and an ABI (PE Applied Biosystems Incorporated) automated sequencer.

### **Isolation of a putative full length cDNA clone for PDE\_XIV**

To facilitate the isolation of a murine full length cDNA for PDE\_XIV containing the full coding region and a terminator codon, the expression of new PDE was determined in a range of tissues using Northern hybridisation. These data (Figures 1 and 2) show that whilst the messenger RNA (length 5.5kb), which hybridises to new PDE, is present in several tissues, it is particularly highly expressed in murine brain, skeletal muscle & liver and at the following stages of embryological development, 10.5, 13.5, 15.5 days. The 13.5 day murine embryonic cDNA library was used in a cDNA positive selection method (GeneTrapper, Life Technologies, Inc.) to isolate the PDE\_XIV. The method was carried out as manufacturers instructions. The original EST sequence of clone 1364394 was in the reverse orientation, therefore, design of the selection oligonucleotide needed to be identical to the coding strand running 5' to 3', this step was critical to the success of the cloning strategy. The oligonucleotide used for the selection and repair is detailed below.

Oligo 1:

Select1 5'-GGT CAC AGA ACT GCC ACT ATG GTT AAA TGT- 3'

5

To isolate the human homologue of the murine PDE\_XIV, PCR primers were designed based on the known EST 1364394 sequence, (Primer 1 and Primer 2) and used to screen a panel of cDNA libraries. PCR's carried out using these primers (the PCR was set up using reagents obtained from a PCR Reagent System kit (Life Technologies) and following the manufacturers instructions, with standard cycling parameters) resulted in the generation of a fragment of the expected size, 164bp, obtained from the human HELA cell line cDNA library(Life Technologies, Inc.), using the same selection/repair oligonucleotide (Oligo 1) the human clone was isolated.

15 Primer 1:

newPDE1 5' -ACC GCT CAG AGA TTT CAC AGC A - 3'

Primer 2:

20

newPDE2 5' -CCC GTC TGA CCC CTT AGT CGT A -3'

Clones were selected for follow up through screening by colony PCR using the above primers and the following method. Using a sterile toothpick a single colony was picked and added to a tube containing 25ul of 1\*PCR supermix (Life Technologies, Inc) & 200nM of primers. The tube was vortex'ed for 1 second, centrifuged for 2 seconds at 14,000 x g. The tubes were then placed in a pre-warmed thermal cycler (MJ Research PTC-200 thermal cycler) 94°C. PCR was performed using the following program: 1 cycle; 94°C, 1 minute, followed by 30 cycles of: 94°C, 30 seconds, 55°C, 30 seconds, 72°C, 1 minute. PCR products were then analysed by gel electrophoresis using standard methods.

30

P5894.GB

Analysis of the isolated murine clone allowed the assembly of a contiguous sequence of 2823 bp which contains an ORF of 446 residues. The full length cDNA sequence for murine PDE\_XIV is presented as SEQ ID No. 5 with the translation of the largest open reading frame within this cDNA presented as SEQ ID No. 1. The coding region is presented as SEQ ID No. 3.

Analysis of the isolated human clone allowed the assembly of a contiguous sequence of 2992 bp which contains an ORF of 288 residues. The cDNA sequence for human PDE\_XIV is presented as SEQ ID No. 6 with the translation of the largest open reading frame within this cDNA presented as SEQ ID No. 2. The coding region is presented as SEQ ID No. 4. This clone has been used to screen a master RNA blot (Clontech) using standard Northern blot methods to identify the tissue distribution for this cDNA. The results (see Figure 3) show that the transcript is highly expressed in the putamen and Caudate nucleus of the brain, in addition to Occipital lobe of the brain, heart, ovary, pituitary gland, kidney, liver, small intestine, thymus, and appendix.

Like all mammalian phosphodiesterases sequenced to date PDE\_XIV contains a conserved catalytic domain sequence of approximately 250 amino acids in the carboxyl-terminal half of the protein that is thought to be essential for catalytic activity. This segment comprises amino acids 108 to 413 in SEQ ID 1 and exhibits sequence conservation with the corresponding region of other PDE's. From the nucleotide alignment (see Figure 4) and the protein alignment (see Figure 5) it is clear to see that the human PDE\_XIV clone is truncated at the 3' end due to a premature stop codon at position 1102bp.

#### Phosphodiesterase assays on crude mammalian cell lysates

Both the murine & human PDE\_XIV cDNA clones were transfected into mammalian COS7 cell line (ATCC) using Lipofectamine (Life Technologies, Inc) and standard methods. The COS7 cells were harvested 72 hr's post transfection and assayed for PDE activity using the following phosphodiesterase activity, a commercially available SPA (scintillation proximity assay) kit (Amersham) for cAMP SPA assay (Amersham). Serial

P5894.GB

dilution's of the cell lysates were made in lysis buffer (50 mM HEPES pH 7.2, 1.92 mM  $\text{MgCl}_2$ , 50 mM KCL, 10 mM EGTA, 1 protease inhibitor tablet/50mls) to dilute out any endogenous inhibitory effects. To 25 ml of diluted crude lysate, 25 ml of buffer D (Buffer C + BSA @ 2mg/ml) was added followed by 50 ml of buffer C (20 mM Tris.HCL (pH 7.4), 5 mM  $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ ) containing 500 nM of cAMP substrate, (20  $\mu\text{l}$  of [ $^3\text{H}$ ] cAMP (1  $\mu\text{M}$ . 4  $\mu\text{Ci/ml}$ ) plus 423  $\mu\text{l}$  of cold cAMP, 10  $\mu\text{M}/5\text{ml}$ ). The reaction was incubated for 30 minutes at 30°C. 50  $\mu\text{l}$  of SPA beads was then added, immediately centrifuged at 2000 rpm for 5 minutes. Reading were collected on a Topcount (Wallac) scintillation counter.

The results (see Figure 6) illustrate that both the human and murine PDE\_XIV clones to be active, 10 fold higher than the mock transfected control.

All publications and patents mentioned in the above specification are herein incorporated by reference.

Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

**SEQUENCE LISTINGS**

The following sequences are presented:

5

SEQ ID No. 1 = murine amino acid sequence

SEQ ID No. 2 = human amino acid sequence

SEQ ID No. 3 = murine coding nucleotide sequence

SEQ ID No. 4 = human coding nucleotide sequence

10 

SEQ ID No. 5 = murine cDNA sequence

SEQ ID No. 6 = human cDNA sequence

**SEQ ID No. 1**

15 MSCLMVERCGEVL FESPEQSVKVCMLGDVRLRGQTGVPAERRGSYPFIDFRLLNNTTHSGEIGTKKKVK 70  
RLLSFQRYFHASRLLRGII PQAPLHLLDEDYLGQARHMLSKVGTWDFDIFLFDRLTNGNSLVTLCHLFN 140  
SHGLIHHFKLDMVTLHRFLVMVQEDYHGHNPHYNAVHAADVQAMHCYLKEPKLASFLTPLDIMLGLLAA 210  
AAHDVDHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEMTQDIEQQLGSLIL 280  
ATDINRQNEFLTRLKAHLHNKDLRLENVQDRHFMLQIALKCADICNPCRIWEMSKQWSERVICEFYRQGD 350  
20 LEQKFELEISPLCNQKDSIPSIQIGFMTYIVEPLFREWARFTGNSTLSENMLSHLAHNKAQWSLLSNQ 420  
HRRRGSGQDLAGPAPETLEQTEGATP 446

**SEQ ID No. 2**

25 MSCLMVERCGEILFENPDQNAKVCMLGDIRLRGQTGVRAERRGSYPFIDFRLLNSTTYSGEIGTKKKVK 70  
RLLSFQRYFHASRLLRGII PQAPLHLLDEDYLGQARHMLSKVGMWDFDIFLFDRLTNGNSLVTLCHLFN 140  
THGLIHHFKLDMVTLHRFLVMVQEDYHSONPHYNAVHAADVQAMHCYLKEPKLASFLTPLDIMLGLLAA 210  
AAHDVDHPGVNQPFILKTNHHLANLYQNMSVLENHHWRSTIGMLRESRLLAHLPKEMTGTWDFDIFLFDRL 280  
LTNGNSLV 288

30

## SEQ ID No. 3

start  
5     ATGCTTGTGTTAATGGTTGAGAGGTGTGGCGAAGTCTTGTTTGAGAGCCCTGAACAGAGTGTCAAA  
TGTGTTTGCATGCTAGGAGATGTACGACTAAGGGGTACAGCGGGGTTCTGCCGAACGCCGTGGCTCCT  
ACCCATTTCATTGACTTCCGTCTACTTAACAATAACAACACACTCAGGGGAAATTGGCACCAGAAAAAGGT  
GAAACGACTGTTAAGTTTCCAAAGATACTTCCATGCATCTAGGCTTCTCCGGGGGATTATACCGCAGGCC  
CCTCTCCACCTGCTGGATGAAGACTACCTTGGACAAGCAAGGCACATGCTCTCAAAGTTGGAACGTGGG  
10    ACTTTGACATTTTCTTGTTTGATCGCTTGACAAATGGGAACAGTCTGGTAACTCTGTTGTGTACCTCTT  
CAACTCCCATTGGGCTCATCCACATTTCAAGCTCGATATGGTGACCTTGACAGGTTTCTGGTTATGGTT  
CAGGAAGATTACCACGGTCACAACCCATACCACAATGCTGTTACGCAGCCGACGTACCCAGGCCATGC  
ACTGTTACCTGAAGGAGCCAAAGTTGGCAAGCTTCTCACACCTCTGGACATCATGCTTGGACTACTGGC  
TGCAAGCAGCTCATGACGTGGACCAACCCAGGGGTCAACCAGCCATTTTGTATCAAACTAACCACCATCTT  
15    GCCAACCTGTATCAGAATATGTCTGTACTGGAGAATCACCCTGGCGATCTACAATTGGCATGCTTCGAG  
AATCAGGGCTCCTGGCTCACTTGCCAAAGGAAATGACACAGGATATCGAACAGCAGCTGGGCTCCCTCAT  
CTTGGCCACGGATATCAACAGACAGAATGAGTTTCTGACCCGCTTAAAAGCTCACCTCCACAATAAGAT  
TTGAGACTGGAGAATGTACAGGACAGACACTTTATGCTTCAGATCGCCTTGAAGTGTGCTGACATTTGCA  
ATCCTTGTCTGATCTGGGAGATGAGCAAGCAGTGGAGTGAAGGGTCTGTGAGGAATTCTACAGACAAGG  
20    TGACCTTGAACAGAAGTTTGAAGTGAATCAGTCTCTTTGTAATCAACAGAAAGATTCAATCCCTAGC  
ATACAAATTGGTTTCATGACTTACATCGTGGAGCCGCTGTTCCGGGAGTGGGCCCGGTTTACTGGGAACA  
GCACCTGTGCGGAGAACATGCTAAGCCATCTCGCGCACAACAAGCCAGTGAAGAGCCTGCTGTCCAA  
TCAGCACAGACGAGGGGCAGCGGCCAGGACCTGGCGGGCCCGCACCTGAGACCTGGAGCAGACAGAA  
GGTGCCACGCCCTAA  
25                   stop

## SEQ ID No. 4

start  
30     ATGCTTGTGTTAATGGTTGAGAGGTGTGGCGAAATCTTGTTTGAGAACCCGA  
TCAGAATGCCAAATGTGTTTGCATGCTGGGAGATATACGACTAAGGGGTACAGCGGGGTTCTGTGCTGAA  
CGCCGTGGCTCCTACCCATTTCATTGACTTCCGCTACTTAACAGTACAACATACTCAGGGGAGATTGGCA  
CCAAGAAAAAGGTGAAAAGACTATTAAGCTTTCAAAGATACTTCCATGCATCAAGGCTGCTTCGTGGAAT  
35    TATACCACAAGCCCTCTGCACCTGCTGGATGAAGACTACCTTGGACAAGCAAGGCATATGCTCTCCAAA  
GTGGGAATGTGGGATTTTGACATTTTCTTGTTTGATCGCTTGACAAATGGAAACAGCCTGGTAACACTGT  
TGTGCCACCTCTTCAATACCCATGGACTCATTCACCATTTCAAGTTAGATATGGTGACCTTACACCGATT  
TTTAGTCATGGTTCAAGAAGATTACCACAGCCAAAACCCGTATCACAATGCTGTTACGCAGCCGACGTC  
ACCCAGGCCATGCACTGCTACCTGAAAGAGCCAAAGCTTGCCAGCTTCTCACGCCTCTGGACATCATGC  
40    TTGGACTGCTGGCTGCAGCAGCACAGATGTGGACCACCCAGGGGTGAACCAGCCATTTTGTAAAAAC  
TAACCACCATCTTGAAACCTATATCAGAATATGTCTGTGCTGGAGAATCATCACTGGCGATCTACAATT  
GGCATGCTTCGAGAATCAAGGCTTCTTGCTCATTTGCCAAAGGAAATGACGTAA  
                                 stop



	AGGTACGCTGCAGGTACC	CGGTCCGGAATCCCGGGTGCACCCACGCGTC	CGGCCAGCCTCCCAGGCCGG	70
	CTGCCTGCTCACCCAGCCAGT	CGCTAGCTCTGGGCACTGCAGCAGGCTCGGCTCTGT	CCCCAGCGCTCGCT	140
5	TGCTTGCTCGCTCGCTCGGCT	GGGAGAAAAGTGGTGTCTCGCCAGAGAGCCTCTCTCT	CCTTCTCTTTTAAATTTTC	210
	TTTTCTCGAGCTCTCTGAGT	CCCTTTGGCGTTTCTTTCTTTCTTTCTTTTCTTTTCTTTTCTTTTCTATA	AAAACTTGCATAATTATACTGCTAATCCTGGATGAGGTTGCTGGATTCTGCAGCACA	280
	AATCTTCATGAACAAGCCGCACCGCT	CAGAGATTTACAGCATTTCAAAGGTCACAGA	ACTGCCACTATGG	350
	start			420
10	TTAAATGCTCTTGTTTAATGGTTGAGAGGTGTGGCGAAGTCTTGTTTGAGAGCCCTGAACAGAGTGTCAA			490
	TGTGTTTGCATGCTAGGAGATGTACGACTAAGGGGT	CAGACGGGGGTTCTGCCGAACGCCGTGGCTCCT		560
	ACCCATTCACTGACTTCCGTCTACTTAACAATACAACACACTCAGGGGAAATGGCACCAAGAAAAAGGT			630
	GAAACGACTGTAAAGTTTCAAAGATACTTCCATGCATCTAGGCTTCTCCGGGGGATTATACCGCAGGCC			700
	CCTCTCCACCTGCTGGATGAAGACTACCTTGGACAAGCAAGGCACATGCTCTCCAAAGTTGGAACGTGGG			770
15	ACTTTGACATTTTCTTTGTTGATCGTTTGACAAATGGGAACGCTGGTAACTGTTGTGTGCTACCTCTT			840
	CAACTCCCATTGGGCTCATCCACCATTTCAAGCTCGATATAGTGACCTTGCACAGGTTTCTGGTTATGGTT			910
	CAGGAAGATTACCACGGTCAACAACCCATACCACAATGCTGTTTACGCGACGCCGACGTCAACCAGGCCATGC			980
	ACTGTTACCTGAAGGAGCCAAAGTTGGCAAGCTTCTCACACCTCTGGACATCATGCTTGGACTACTGGC			1050
	TGCAGCAGCTCATGACGTGGACCACCCAGGGGTCAACCAGCCATTTTGGATCAAACTAACCAACCATCTT			1120
20	GCCAACCTGTATCAGAATATGTCTGTACTGGAGAATCACCCTGGCGATCTACAATTGGCATGCTTCGAG			1190
	AATCACGGCTCCTGGCTCACTTGCCAAAGGAAATGACACAGGATATCGAACAGCAGCTGGGCTCCCTCAT			1260
	CTTGGCCACGGATATCAACAGACAGAATGAGTTTCTGACCGCTTAAAGCTCACCTCCACAATAAAGAT			1330
	TTGAGACTGGAGAATGTACAGGACAGACACTTTATGCTTCAGATCGCCTTGAAGTGTGCTGACATTTGCA			1400
	ATCCTTGTGCTATCTGGGAGATGAGCAAGCAGTGGAGTGAAGGGTCTGTGAGGAATTCTACAGACAAGG			1470
25	TGACCTTGAACAGAAGTTTGAAGTGGAAATCAGTCCTCTTTGTAATCAACAGAAAGATTCAATCCCTAGC			1540
	ATACAAATTTGGTTTCATGACTTACATCGTGGAGCCGCTGTTCCGGGAGTGGGCCGGTTTACTGGGAACA			1610
	GCACCCTGTCTGGAGAACATGCTAAGCCATCTCGCGCACAAAGGCCAGTGAAGAGCCTGCTGTCCAA			1680
	TCAGCACAGACGCGGGGAGCGGCCAGGACCTGGCGGGCCCCGCACCTGAGACCTGGAGCAGACAGAA			1750
	stop			
30	GGTGCCACGCCCCAAGGTAGTGTCTGCTGATGCACGGCCATCTGTCCGTCCACAGGAGCACGGCCATCC			1820
	GTCCGACTGCCCCGCAACAAGCCCATCACGCTGGGTTTCGATGCCATCCGCTGCCACTTACCGCTCC			1890
	CTTCGTTGATCCAAGTGTACAAAAGCCATTGTACCTCAGCATTAGCTGCCGAAATGGGCGGCTCTATCC			1960
	CGTCATTGGAGCTGATTCTGGGGCGGCTGCCCAACCGAAACGCCTGGAAGTAAGAAAGGGGTGCTTCTG			2030
	CCGTGTTGCGCTCTGGCCCTTGGTCACGCTGACTGGCAGTAGCTCCTAAGTCCAGAGCATTTTAACGTTT			2100
35	GCCATCGGACAGCTGACCTGCATGACACCAGCATACTTGGAACTGCAAACTGGTCTTGCGTGCCAGAGC			2170
	ACAAACGAGAGTGTGAGAGAAAGTACCTTCTATTTTAATAATAATTATTATATAAAATAATAATCTTT			2240
	TTAACTTTTATATTTTCATGCACCAGACAATGGGTCTAAAACTTTGGACAAGTAATACTCTGCGTACCCAA			2310
	ACCTAAGAGGGGGTTCAATTATTTTGTATTGACTCTATGCCACATTGGGTCCGAGATGTGGCACCATTCG			2380
	GATTTCTGAAACCACGCGTCCCCTCCCATCTGGTGAAGGTGCTGTACAGCCCGTCCCCTTGCACCGTTA			2450
40	GCCAATCCGTCTTTTACGGATTCACTGACCTGTTTATATTCAAGTGTACATTTTCTGTAATACCAAA			2520
	CGCTACTGATTCCCATGCCAAAATACACGAGTATTATGGGATTGCTACCTGTATAAACAATGGCACTGTG			2590
	AACGAATACCTGTTAGTTTTAATACAAGAGAATGCATTTGTAATATGGTATAGAGTTTATTAATATACT			2660
	GTTGTTCTGCAGATAAAGGCCTTAACCTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGGGG			2730
	CGGCGCGCTAGAGGATCCCTCGAGGGGCCAAGCTTACGCGTGCATGCGACGTCATAGCTCTCTCCCTA			2800
45	TAGTGAGTCGTATTATAAGCTAG	2823		

	CGGAATTTCGATGCACATGCAGCAGGCTCGGCTCTGTCCGACCACTTGTCTGGGAGAAAAGTGGTGTACTC	70
	ACCCAGGGAGAGTCTCTCTTTCTACCTTCTTCTTCTCGATCTCCTTGTGTGCTTTTGTGTTCTTTAT	140
5	TTCTTTTCTTTTTTTCTTTTTTTTTTTGTTACTTAATTATATTCCTAATCCTGGATGAAGTTGCTGG	210
	ATTCTGCAGCACAAAGTCTTCATGAACAAGCAGCACCGCTCAGAGATTTACGGCATTCAAAGGTCACAGA	280
	start	
	ACTGCCACTATGGTTAAATGTCTTGTTTAAATGGTTGAGAGGTGTGGCGAAATCTTGTTTGAACCCCGA	350
	TCAGAATGCCAAATGTGTTTGCATGCTGGGAGATATACGACTAAGGGGTACAGACGGGGTTCGTGCTGAA	420
10	CGCCGTGGCTCCTACCCATTCATTGACTTCCGCTACTTAACAGTACAACATACTCAGGGGAGATTGGCA	490
	CCAAGAAAAAGGTGAAAAGACTATTAAGCTTTCAAAGATACTTCCATGCATCAAGGCTGCTTCGTGGAAT	560
	TATACCACAAGCCCCTCTGCACCTGCTGGATGAAGACTACCTTGGACAAGCAAGGCATATGCTCTCCAAA	630
	GTGGGAAGTGTGGGATTTTACATTTCTTGTTTGATCGCTTGACAAATGGAAACAGCCTGGTAACACTGT	700
	TGTGCCACTCTTCAATACCCATGGACTCATTCACCTTTCAAGTTAGATATGGTGACCTTACACCGATT	770
15	TTTAGTCATGTTTCAAGAAGATTACACAGCCAAAACCGTATCACAATGCTGTTACGCAGCCGACGTC	840
	ACCCAGGCCATGCACGTCTACCTGAAAGAGCCAAAGCTTGCCAGCTTCTCACGCCCTCTGGACATCATGC	910
	TTGGACTGCTGGCTGCAGCAGCACAGTGTGGACCACCCAGGGGTGAACCAGCCATTTTGTAAAAAAC	980
	TAACCACCATCTTGAAACCTATATCAGAATATGTCTGTGCTGGAGAATCATCACTGGCGATCTACAATT	1050
	stop	
20	GGCATGCTTCGAGAATCAAGGCTTCTTGCTCATTTGCCAAAGGAAATGACGTAAGTGCTGCCGAGATGAA	1120
	ACATACTGATGTGCATGCAGTAAAGATAAGCCACTTTCTCTAGGGCAGGCTTGGGACCTTTTTCGTGAAT	1190
	GGCAGAGAGCCCCCGGCTGTACTTCTTGCTGCAGTGAAGTGTCTATCAGAGGAGATTTGGTGTGAGTT	1260
	ACAGCAACCCAGAAACCAAAATCTCTGTGTGCTTTGAAAGGGCTTGCAGAGTCAATGACCTACAGTC	1330
	AGGAAAAGGGATAATAACAGCTCTCAGTTTTACACGCTTCAGATTCAAGTGTCTCAACTTGGCAAAATTC	1400
25	CCGACCTTTAGTTTGTGCAAAATTTGCTCTTCCATGTAGCTTCAAATAGTAAATATTTATCAAGAAGGAACC	1470
	CAGGCATTCTAAAGCTAGAGTTCAAAAAAGTATATTTGTAAATTGCTAGTCTCAGCAAAAAATAGAAGTCA	1540
	GAAATCTTTTCTAAATATGCTTTTGCTAAGTAATTGAAATGGCCCTAGCATTTTTTTCACCAATTAATT	1610
	TACCTTACGCTCTCTTGCACTTTAAACAGAAGGGGAGACACTCATTTTCTGGTTCACTATTTGATAGCCAT	1680
	GGTATGTAGGCTGAGTCCCACTAAATCTGAGGCCATTGTTTCATTTTCTGGTGGCCCCAAGTTAGCTGC	1750
30	TAATACTGTCTTCCAAGGCCACCATTAATTCGTATCTGTTTAAATGAACACGTGCAGAACCCAAGAAACCT	1820
	AGGTGAAAAGAGTACATAGATTGCTGTACCCCTTCTTCAAGACAAGCACATAACTTGAGGTCAAGGACCAA	1890
	GTGCTGTCTCCCACTGAACAAGCAGTATACTCTGGGTTGTGGATTGATTCTGGCCCTCTGATTTGATC	1960
	TCATGCTGTTTCTAGCACCCAGAGGAATGTGAAATTTGCAGGAGGAATTCAGTTCTGATAAAATTTTA	2030
	CTCCCTGGAACATAAAACCAGTTCTCGTGATGGAATAAAAACTTATGCCTTCTACTAGAATTAATAA	2100
35	ATTGCAAGAGATTGAAAGAATTAATGTCAAAAAGAACTAAAACTAGAGCAAAAGACTCAAGTGAGAAGAAG	2170
	AAAAGAGGAGGTAAGGAGAGAGACAAGGAAGAAAGAGGAGAAGGAAGGAAGAATAGTGAGGACAGGAA	2240
	AGAAGAAAAATGCAAGGGAAATGGGAAAGGACTCTGGGGTGACCAGACTTCTCTGGTCAGTACCTGCATT	2310
	CATCCTGTTTGTACTCAATATTTCTTTCTAAATATTCATTTACATCTATGGATTCCAATGAAAAAT	2380
	ATATTTTATGTGCTTTGTGGAACACAGTGTATAAATTGTTTTGCCAGAAGAATAATTGTTATACAA	2450
40	TAATATATGTGAAAACCTTTATTACAAAAGCCATTATCATAATCATTATTATTCCTTCTATCACAGGTA	2520
	TGCTTTAATGTCATTTTTCTGATTTTAAAAGTAGGGCAGGTTAATTGTAGAAAGTAAGGAAAAATTCAGGA	2590
	AAGTGTTAGTTTGAACATATGTAAGTTGCTCTTTTTAAGGGCCAAAAACAGGAGACTTTTAGCACTTTCA	2660
	TATGTTTCAGCTTGATATGAAAGAGAAAACGAACTGCTAGTAATCTGCCATCCAGGTATAGTTCATG	2730
	TTAACCTGGCTAGTTTATTTCTTTTAGCTTTTTTCAATACAAACTATTTTAAACAAAATGATTATATA	2800
45	TTTGGGAAACCTATTTTACAGTTTACGTCTAGAAATTTTTTATACAAATAAGAGCTTTTTTCCAAATCA	2870
	AAAAAAGAAAAAAGGGCGCCGCTCTAGAGGATCCCTCGAGGGGCCCAAGCTTACGCGTGCATGCGACG	2940
	TCATAGCTCTCTCCCTATAGTGAGTCGTATTATAAGCTAGGCCTGGCCGTC	2992

**CLAIMS**

1. An amino acid sequence comprising the sequence presented as Formula I or a  
5 variant, homologue, fragment or derivative thereof.
2. An amino acid sequence comprising the sequence presented as Formula I.
3. A nucleotide sequence encoding the amino acid sequence as defined in claim 1 or  
10 claim 2.
4. A nucleotide sequence comprising the sequence presented as SEQ ID No. 3 or SEQ  
ID No. 4 or a variant, homologue, fragment or derivative thereof.
- 15 5. A nucleotide sequence comprising the sequence presented as SEQ ID No. 3 or SED  
ID No. 4.
6. A nucleotide sequence that is capable of hybridising to the nucleotide sequence  
according to any one of claims 3 to 5.  
20
7. A nucleotide sequence that is capable of hybridising to the nucleotide sequence  
according to claim 6.
8. A vector comprising the nucleotide sequence according to any one of claims 3 to 7.  
25
9. A host cell into which has been incorporated the nucleotide sequence according to  
any one of claims 3 to 7.

10. An assay method for identifying an agent that can affect PDE\_XIV activity or expression, the assay method comprising

contacting an agent with an amino acid according to claim 1 or claim 2 or a  
5 nucleotide sequence according to any one of claims 3 to 7; and

measuring the activity or expression of PDE\_XIV;

wherein a difference between a) PDE activity or expression in the absence of the agent and  
10 b) PDE activity or expression in the presence of the agent is indicative that the agent can affect PDE\_XIV activity or expression.

11. An assay method according to claim 10 wherein the assay is to screen for agents useful in the treatment of any one or more of a CNS disorder, a cardiovascular disorder, a  
15 GI disorder, cancer, a sexual dysfunction.

12. A process comprising the steps of:

- (a) performing the assay according to claim 10 or claim 11;  
20 (b) identifying one or more agents that do affect PDE\_XIV activity or expression; and  
(c) preparing a quantity of those one or more identified agents.

25 13. A method of affecting *in vivo* PDE\_XIV activity or expression with an agent;

wherein the agent is capable of affecting PDE\_XIV activity or expression in an *in vitro* assay method;

30 wherein the *in vitro* assay method is the assay method defined in claim 10 or claim 11.

P5894.GB

14. Use of an agent in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE\_XIV, the agent is capable of having an effect on the activity or expression of PDE when assayed *in vitro* by the assay method according to claim 10 or claim 11.

5

15. An enzyme capable of having an immunological reaction with an antibody raised against PDE\_XIV.

10

16. A nucleotide sequence coding for a PDE, wherein the nucleotide sequence is obtainable from NCIMB 40995 or NCIMB 40996.

17. A PDE wherein the PDE is expressable from a nucleotide sequence obtainable from NCIMB 40995 or NCIMB 40996.

15

18. Use of an agent which has an effect on the activity of PDE\_XIV or the expression thereof in the preparation of a pharmaceutical composition for the treatment of a disease or condition associated with PDE\_XIV.

20

19. A recombinant PDE\_XIV enzyme.

20. A recombinant nucleotide sequence encoding a PDE\_XIV enzyme.

21. A PDE\_XIV enzyme substantially as described herein.

25

**ABSTRACT**

ENZYME


- 5    Amino acid sequences and nucleotide sequences are described. The amino acid sequences  
comprise the sequence presented as SEQ ID No. 1 or SEQ ID No. 2 or a variant,  
homologue, fragment or derivative thereof.

10

15

Fig 1

Murine MTN Blot  
probed with  $^{32}\text{P}$ -labelled  
murine PDE<sub>XIV</sub>




**THIS PAGE BLANK (USPTO)**




Fig 2

Murine Embryo MTN Blot  
 probed with  $^{32}\text{P}$ -labelled  
 murine PDE\_XIV



**THIS PAGE BLANK (USPTO)**

**Figure 3**  
**Human RNA Master Blot probed with  $^{32}\text{P}$ -labelled**  
**human PDE\_XIV**



**THIS PAGE BLANK (USPTO)**

Pileup: Genetics Computer Group.

MSF: 3134 Type: N Check: 5422 ..

5

Name: mpdea\_oo Len: 3134 Check: 5084 Weight: 0.001  
 Name: hspdea\_oo Len: 3134 Check: 338 Weight: 0.100

```

10  new mpde_      1 AGGTACGCCT GCAGGTACCG GTCCGGAATT CCCGGGTCGA CCCACGCGTC
    new hspde_      .....

    new mpde_      51 CGGCCAGCCT CCCAGGCCGG CTGCCTGCTC ACCCAGCCAG TCGCTAGCTC
    new hspde_      1 ..... CGGAAT.TC

15  mpdea_        101 TGGGCACTGC AGCAGGCTCG GCTCTGTCCC AGCGCTCGCT TGCTTGCTCG
    hspde_          9 GATGCACTGC AGCAGGCTCG GCTCTGTCCC AGC....A..

    mpdea_        151 CTCGCTCGGC TGGGAGAAAA GTGGTGTC.C TCGCCCAG.. AGAGCCTCTC
    hspde_        43 ....CTTGTC TGGGAGAAAA GTGGTGTTAC TCACCCAGGG AGAGTCTCTC

20  mpdea_        198 TCTC..CCTT CCTTCTTTCT CGAGCTCTCT GAGTCCTTTG GCGTTTCTTT
    hspde_        89 TTTCTACCTT CCTTCTTTCT CGATCTCCTT GTGTGCTTTT GTGTTTCTTT

    mpdea_        246 CTTTCTTTCC TTTTTTTTTT TTTTTTAATA TTTTCTTTT CTTTCTATAA
25  hspde_        139 ATTTCTTTTC CTTTTTTTTC TT..... TTTTTTTTTT GTTACT....

    mpde_         296 AACTTGCATA ATTATACTGC TAATCCTGGA TGAGGTTGCT GGATTCTGCA
    hspde_        177 .....TA ATTATATTCC TAATCCTGGA TGAAGTTGCT GGATTCTGCA

30  mpde_         346 GCACAAATCT TCATGAACAA GCCGCACCGC TCAGAGATTT CACAGCATTC
    hspde_        219 GCACAAGTCT TCATGAACAA GCAGCACCGC TCAGAGATTT CACGGCATTC

                                start codon
35  mpde_         396 AAAGGTCACA GAACTGCCAC TATGGTTAAA TGTCTTGTTT AATGGTTGAG
    hspde_        269 AAAGGTCACA GAACTGCCAC TATGGTTAAA TGTCTTGTTT AATGGTTGAG

    mpde_         446 AGGTGTGGCG AAGTCTTGTT TGAGAGCCCT GAACAGAGTG TCAAATGTGT
    hspde_        319 AGGTGTGGCG AAATCTTGTT TGAGAACCCC GATCAGAATG CCAAATGTGT

40  mpde_         496 TTGCATGCTA GGAGATGTAC GACTAAGGGG TCAGACGGGG GTTCCTGCCG
    hspde_        369 TTGCATGCTG GGAGATATAC GACTAAGGGG TCAGACGGGG GTTCGTGCTG

    mpde_         546 AACGCCGTGG CTCCTACCCA TTCATTGACT TCCGTCTACT TAACAATACA
    hspde_        419 AACGCCGTGG CTCCTACCCA TTCATTGACT TCCGCCTACT TAACAGTACA

45  mpde_         596 ACACACTCAG GGGAAATTGG CACCAAGAAA AAGGTGAAAC GACTGTTAAG
    hspde_        469 ACATACTCAG GGGAGATTGG CACCAAGAAA AAGGTGAAAA GACTATTAAG

    mpde_         646 TTTCAAAGA TACTTCCATG CATCTAGGCT TCTCCGGGGG ATTATACCGC
50  hspde_        519 CTTTCAAAGA TACTTCCATG CATCAAGGCT GCTTCGTGGA ATTATACCAC

    mpde_         696 AGGCCCTCT CCACCTGCTG GATGAAGACT ACCTTGACA AGCAAGGCAC
    hspde_        569 AAGCCCTCT GCACCTGCTG GATGAAGACT ACCTTGACA AGCAAGGCAT

55  mpde_         746 ATGCTCTCCA AAGTTGGAAC GTGGGACTTT GACATTTTCT TGTTTGATCG
    hspde_        619 ATGCTCTCCA AAGTGGGAAT GTGGGATTTT GACATTTTCT TGTTTGATCG
  
```

**THIS PAGE BLANK (USPTO)**

P5894.GB

	mpde_	796 CTTGACAAAT GGGAACAGTC TGGTAACTCT GTTGTGTAC CTCTTCAACT
	hspde_	669 CTTGACAAAT GGAAACAGCC TGGTAACT GTTGTGCCAC CTCTTCAATA
5	mpde_	846 CCCATGGGCT CATCCACCAT TTCAAGCTCG ATATGGTGAC CTTGCACAGG
	hspde_	719 CCCATGGACT CATTACCAT TTCAAGTTAG ATATGGTGAC CTTACACCGA
	mpde_	896 TTTCTGGTTA TGGTTCAGGA AGATTACCAC GGTCAACAAC CATAACCACAA
	hspde_	769 TTTTGTAGTCA TGGTTCAGGA AGATTACCAC AGCCAAAACC CGTATCACAA
10	mpde_	946 TGCTGTTTAC GCAGCCGACG TCACCCAGGC CATGCACTGT TACCTGAAGG
	hspde_	819 TGCTGTTTAC GCAGCCGACG TCACCCAGGC CATGCACTGC TACCTGAAAG
	mpde_	996 AGCCAAAGTT GGCAAGCTTC CTCACACCTC TGGACATCAT GCTTGGAATA
	hspde_	869 AGCCAAAGCT TGCCAGCTTC CTCACGCCTC TGGACATCAT GCTTGGAATA
15	mpde_	1046 CTGGCTGCAG CAGCTCATGA CGTGGACCAC CCAGGGGTCA ACCAGCCATT
	hspde_	919 CTGGCTGCAG CAGCACACGA TGTGGACCAC CCAGGGGTGA ACCAGCCATT
20	mpde_	1096 TTTGATCAAA ACTAACCACC ATCTTGCCAA CCTGTATCAG AATATGTCTG
	hspde_	969 TTTGATAAAA ACTAACCACC ATCTTGCCAA CCTATATCAG AATATGTCTG
	mpde_	1146 TACTGGAGAA TCACCACTGG CGATCTACAA TTGGCATGCT TCGAGAATCA
	hspde_	1019 TGCTGGAGAA TCATCACTGG CGATCTACAA TTGGCATGCT TCGAGAATCA
25	mpde_	1196 CGGCTCCTGG CTCACTTGCC AAAGGAAATG ACACAGG... ..ATATC
	hspde_	1069 AGGCTTCTTG CTCATTTGCC AAAGGAAATG ACGTAAAGTC TGCCGAGATG stop codon
30	mpde_	1238 GAACA.....GCA... ..GCTG GGCTCCCTCA TCTTGGCCAC
	hspde_	1119 AAACATACTG ATGTGCATGC AGTAAAGATA AGCCACTTTC TCTAGGGCA.
	mpde_	1270 GGATATCAAC AGACAGAATG AGTTTCTGA. ....CCCG CTTAAAGCT
	hspde_	1168 GGCTTGGGAC CTTTTCGTG AATGGCAGAG AGCCCCCGG CTGTACTTCC
35	mpde_	1313 CACCTCCACA ATAAAGATT. TGAGAC.... ..TGGAGAAT GT.ACAGGA.
	hspde_	1218 TGCCTGCACT GAGCTGTCTA TCAGAGGAGA TTTGGTGTCA GTTACAGCAA
	mpde_	1354 ..CAGACACT TTATGCT.TC AGATCGCCTT GAAGTGTGCT GACATTTGCA
	hspde_	1268 CCCAGAAACC AAAATCTCTC TGTGTGCTTT GAAAGGGCCT TGCAGAGTCA
40	mpde_	1401 AT..CCTT.. GTC.GTATCT GGGAGATGAG CAAGCAGT.. GGAGTGAAAG
	hspde_	1318 ATGACCTACA GTCAGGAAAA GGGATAATAA ACAGCTCTCA GTTTTCACAC
	mpde_	1444 GGT..... CTGTGAGGAA TTCTACAGAC AAGGTGACCT TGAAC..AG.
45	hspde_	1368 GCTTCAGTAT CAGTGCTCAA CTTTGCCAAA TTCCCGACCT TTAGTTTAGC
	mpde_	1484 AAGTTTGAAC TGGAAATCAG .TCCTCTTTG TAATCAAC.A GAAAGATTCA
	hspde_	1418 AAAATTGTCC TTCCATGTAG CTCCAAATAG TAAATATTTA TCAAGAAGGA
50	mpde_	1532 ATCCCTAGCA TACAAA...T TGGTTTCATG ACT.TACATC GTGGAGCCGC
	hspde_	1468 A.CCCAGGCA TTCTAAAGCT AGAGTTCAAA AAAGTATATT TTGTAATTGC
	mpde_	1578 TGTTCCGGG. ...AGTGG.. GCCCGGTTTA CTGGG..AAC AGCACCTGT
	hspde_	1517 TAGTCTCAGC AAAAATAGAA GTCAGAAATT CTTTCTAAA ATGTCTTTTG
55	mpde_	1620 CGGAGAACAT GCTAAGCC... ..ATCTCG CGCACAACAA AGCCAGTGG
	hspde_	1567 CTAAGTAATT GAAATGGCCC TAGCATTTTT TTCACCAATT AATTACCTT

**THIS PAGE BLANK (USPTO)**



P5894.GB

	mpde_	1664	AAGAGCCT.G	CTGTCCAATC	AGCAC...AG	ACGCA.....	GGGGCAG
	hspde_	1617	ACGTCTCTTG	CACCTTAAAC	AGAAGGGGAG	ACACTCATTT	TCTGGTTCAC
5	mpde_	1702	CG.....G	CCAGGACCTG	GCGG...GC	CCCGC...AC	CTGAGACCCT
	hspde_	1667	TATTTGATAG	CCATGGTATG	TAGGCTGAGT	CCCACTAAAT	CTGAGGCCAT
				stop codon			
10	mpde_	1738	GGAG.CAGAC	AGAAGGTGCC	ACGCCCIAAG	GTAGCTGTC.	TGCTGA..T
	hspde_	1717	TGTTTCATTT	TCCTGGTG..	..GCCCAAG	TTAGCTGCTA	ATACTGTCTT
	mpde_	1783	GCACGGCCA.	.....TCT	G.TCCGTCCA	.....CAGGA	GCACGGCC..
	hspde_	1763	CCAAGGCCAC	CATTAATTCT	GATCTGTTTA	ATGAACACGT	GCAGAACCCA
15	mpde_	1817	...ATCC...	.....G	TCC...GACT	GC.....	.CCTCGCAAC
	hspde_	1813	AGAAACCTAG	GTGAAAAGAG	TACATAGATT	GCTGTACCCT	TCTTCAAGAC
	mpde_	1840	AAGCCCATCA	CGTGGGTGT	CGATGCCAT.	.CCGCTGCC	A.CTTACC..
	hspde_	1863	AAGCACATAA	CTTGAGGTCA	AGGACCAAGT	GCTGTCTCCC	AACTGAACAA
20	mpde_	1885	...GCCTCCC	TTCGTTGATC	CAAGTGTACA	AAAGCCATTG	...TCACCTC
	hspde_	1913	GCAGTATACT	CTGGGTGTG	GATTGATTCC	TGGCCCTCTG	ATTTGATCTC
	mpde_	1929	AGCAT.....	.TAGCTGCC.	..GAAATGGG	CGGCTCTATC	CCGTCAATTG
25	hspde_	1963	ATGCTGTTTC	CTAGCACCCA	GAGGAATGTG	AAATTGTCAG	GAGGAATTC
	mpde_	1970	AG..CTGAT.	...TCTGGGG	CGGCTGCCCC	AACCGAAAC.	.....G
	hspde_	2013	AGTTCTGATA	AATTTTACT	CCCTGGAAC	AAATAAAACC	AGTTCTCGTG
30	mpde_	2004	CCTGGAAGTA	AGAA..AGGG	GTGCTTCTGC	CGTGTTCGCC	TCTGGCCCTT
	hspde_	2063	CATGGAATAA	AAACTTATGC	CTCTTACTAG	AATAATAAAT	TGCAAAGATT
	mpde_	2052	GGTCACGCTG	ACTGGCAGTA	GCTCCTAAGT	CCAGAGCATT	TTAACGTTTG
	hspde_	2113	GAAAGAATTA	AATGCAAAAA	GAACTAAAAA	CTAGAGCAAA	AGATCAAGTG
35	mpde_	2102	CCATC..GGA	CAGCTGACCT	...GCATGAC	ACCAGCAT..	.ACTTGGAAC
	hspde_	2163	AGAAGAAGAA	AAGAGGAGGT	AAGGAGAGAG	ACAAGGAAGA	AAGAAGGAGA
	mpde_	2144	TGCAAACTG	GTCTTGCGTG	CCAGAGCACA	AACGAGAGTG	TGAGAGAAA.
40	hspde_	2213	AGGAAAGGAA	GAATAGTGAG	G.ACAGGAAA	GAAGAAAATG	CAAGGGAAAT
	mpde_	2193	..GTACCTTC	TATTT..TAA	TAATAATTAT	TATTATAAAA	TA....ATAA
	hspde_	2262	GGGAAAGGAC	TCTGGGGTGA	CCAGACTTCT	CCTGGTCAGT	ACCTGCATTC
45	mpde_	2235	ATCTTTTTAA	CTTTT..ATA	TTTCATGCAC	CAGACAATGG	GTCTAAAACT
	hspde_	2312	ATCCTGTTTG	TTACTCAATA	TTTCTTTCCT	AAAATATTCA	TTTCACATCT
	mpde_	2283	TTGGA...CA	AGTAATACTC	TGCGTACCCA	AACCTAAGAG	G.....GGG
	hspde_	2362	ATGGATTCCA	ATGAAAAATA	TATTTTATG	TGTCTTTGTG	GAACACAGTG
50	mpde_	2324	TTC...ATTA	TTTT.GCTAT	T.GACTC...	..TATGCCAC	ATTGGGTCCG
	hspde_	2412	TTATAAATTG	TTTTTGCCAG	AAGAATAATT	GTTATACAAT	AATATATGTG
	mpde_	2364	AGA..TGTGG	CACCATTGCG	ATTTCTGAAA	CCACGCGTCC	.CCTCCCATC
55	hspde_	2462	AAAACCTTAT	TACAAAAGCC	ATTATCATAA	TCATTATTAT	TCCTTCTATC
	mpde_	2411	TGGTGAAGG	TGCTGTACAG	CCCGTCCC..	..TTTGCACC	GTTAGCCAAT
	hspde_	2512	ACA.GGTAAA	TGCTTTAATG	TCATTTTCT	GATTTTAAAA	GTAGGGCAGG

**THIS PAGE BLANK (USPTO)**

	mpde_	2457	CCGTCITT..	....TACGGA	...TTCAGTG	ACCTGTTTAT	ATTCACAA.G
	hspde_	2561	TTAATTGTAG	AAAGTAAGGA	AAATTCAGGA	AAGTGTTAGT	TTGAACTATG
5							
	mpde_	2497	TGTACATTTT	CTGT..AAAT	ACCAAACGCT	ACTGA.....	.....TTCC
	hspde_	2611	TGAAGTTGCT	CTTTTAAAGG	GCCAAAAACA	GGAGACTTTT	AGCACTTTCA
10	mpde_	2534	CATGC..CA.	....AAATAC	ACGAGTATTA	TGGGATTGCT	A.....CCTG
	hspde_	2661	TATGTTTCAG	CTTGATATGA	AAGAGAAAAC	TGAAACTGCT	AGTAATCCTG
	mpde_	2571	.....T	ATAACAATG	GCACTGTGAA	CAGAATA...	.CTGTTAGTT
	hspde_	2711	CCATCCAGGT	ATAGTTCATG	TTAACCTGGC	TAGTTTATTT	TCTTTTAGTC
15	mpde_	2608	TTAATACAAG	AGAATGCATT	TGTAAATATG	GTATAGAGTT	TATTAATATA
	hspde_	2761	TTTTTTCAT	ACAAA.CTTA	TTTTAACAAA	ATAT.GATTA	TATTTGGGGA
	mpde_	2658	CTGTTGTTTCG	CAGATAAAGG	CCTTAACTTT	AAAAAAAAAA	AAAAAAAAAA.
	hspde_	2809	ACTTATTTTA	CAGTTTACGT	CCTGAAATTT	TTTATTTACA	ATAAAGACTT
20							
	mpde_	2708	.....AAAA	AAAAAAAAAA	AAAAAGGGGC	GGCCGCTCTA	GAGGATCCCT
	hspde_	2859	TTTCCAAAT	CAAAAAAAAA	AAAAAGGGGC	GGCCGCTCTA	GAGGATCCCT
	mpde_	2752	CGAGGGGCCC	AAGCTTACGC	GTGCATGCGA	CGTCATAGCT	CTCTCCCTAT
25	hspde_	2909	CGAGGGGCCC	AAGCTTACGC	GTGCATGCGA	CGTCATAGCT	CTCTCCCTAT
	mpde_	2802	AGTGAGTCGT	ATTATAAGCT	AG.....	.....	2823
	hspde_	2959	AGTGAGTCGT	ATTATAAGCT	AGGCACTGGC	CGTC	2992

**THIS PAGE BLANK (USPTO)**

CLUSTAL W (1.7) multiple sequence alignment


35

40

**THIS PAGE BLANK (USPTO)**

Figure 6.

SPA assay to determine the cAMP hydrolytic  
activity of murine and  
human PDE\_XIV.



**THIS PAGE BLANK (USPTO)**